Genetically modified bacteria and methods for genetic modification of bacteria

By genetic modification of Propionibacter acnes, the introduction of inducible promoters and essential protein expressions significantly reduce endogenous pathogenic proteins and secrete mammalian growth factors and cytokines, the delivery of microorganisms in the treatment of skin diseases and Expression problems improve treatment effect.

CN118979001APending Publication Date: 2024-11-19CROWN LABORATORIES INC
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410869004.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2014-06-17
Filing Date
2015-06-17
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The prior art is difficult to effectively utilize microorganisms in the treatment of skin diseases, especially in the treatment of local skin diseases, and lacks efficient biomolecular delivery and expression methods, resulting in poor treatment effects.

Method used

By genetically modifying bacteria, such as Propionibacter acnes, the introduction of inducible promoters and essential proteins, the expression of endogenous pathogenic proteins is significantly reduced or eliminated, and mammalian growth factors and cytokines such as IL-10 , VEGF, etc., are used for the treatment of local skin diseases.

Benefits of technology

It realizes efficient delivery of microorganisms on the skin and expression of biomolecules, significantly improves the therapeutic effect of local skin diseases, enhances the absorption and utilization of biomolecules, and improves the targetedness and efficiency of treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

Microorganisms may be genetically modified to express biomolecules that are beneficial to mammals and / or to significantly reduce or eliminate expression of harmful virulence factors. The growth and viability of such genetically modified microorganisms can be optionally modulated by introducing an inducible promoter that modulates the expression of proteins that are necessary for the growth and viability of these microorganisms. Compositions comprising such genetically modified microorganisms and methods of making and using these compositions are disclosed in the invention.
Need to check novelty before this filing date? Find Prior Art

Description

This application is a divisional application of the invention patent application with application number 201580031622.3, application date June 17, 2015, applicant is Crown Laboratories Ltd., and invention name is "Genetically modified bacteria and methods for genetic modification of bacteria". Related Applications

[0001] This application claims priority to U.S. Provisional Patent Application No. 62 / 013,159, filed on June 17, 2014. The entire contents of the above application are incorporated herein by reference, including all text, tables, sequence listings, and figures. Sequence Listing

[0002] This application is submitted with a sequence listing. The sequence listing is submitted electronically in ASCII format as a text file via EFS-Web. The ASCII copy was created on June 16, 2015, named XycrobeSeqListing0439565.1.txt, is 806 kb in size, and its entire contents are incorporated herein by reference. introduce

[0003] The present disclosure relates to compositions comprising genetically modified microorganisms, methods of making genetically modified microorganisms, and uses thereof.In some aspects, the subject matter described herein relates to the field of dermatology and compositions for topical dermatological uses. Summary of the invention

[0004] The present invention provides genetically modified microorganisms. In a specific embodiment, the microorganism is a bacterium of the genus Propionibacterium. In various aspects, the genetically modified bacteria of the genus Propionibacterium include nucleic acids encoding mammalian growth factors or mammalian cytokines. In some aspects, the growth factor is a hormone. In some aspects, the growth factor is a human hormone or a bovine hormone. In certain embodiments, the growth factor is a somatotropin. In some embodiments, the growth factor includes SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48 or SEQ ID NO:49. In certain embodiments, the growth factor is secreted by bacteria. In some embodiments, the growth factor is a human growth factor. In certain embodiments, the growth factor is transforming growth factor β (TGF-β), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), fibroblast growth factor (FGF), insulin-like growth factor-1 (IGF1), platelet-derived growth factor (PDGF), granulocyte monocyte colony stimulating factor (GMCSF), epidermal growth factor (EGF) and / or human growth hormone (HGH). The growth factor can be a transforming growth factor comprising any one of SEQ ID NO:63 to SEQ ID NO:69. In some embodiments, the growth factor is a hepatocyte growth factor comprising SEQ ID NO:70. In some embodiments, the growth factor is a vascular endothelial growth factor (VEGF) comprising any one of SEQ ID NO:71 to SEQ ID NO:91. In some embodiments, the growth factor is a platelet-derived growth factor (PDGF) comprising any one of SEQ ID NO:93 to SEQ ID NO:102. In certain embodiments, the growth factor is an epidermal growth factor (EGF) comprising any one of SEQ ID NO:103 to SEQ ID NO:106. In some embodiments, the fibroblast growth factor (FGF) comprises any one of SEQ ID NO:107 to SEQ ID NO:144. In some embodiments, one or more bacteria secrete mammalian growth factors or mammalian cytokines. In some embodiments, the mammalian cytokine is an immunosuppressive cytokine. In some embodiments, the mammalian cytokine is a human cytokine. In certain embodiments, the cytokine is selected from interleukin-10 (IL-10), interleukin-6 (IL-6), interleukin-7 (IL-7), and interleukin-8 (IL-8). In some embodiments, the cytokine is selected from SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, and SEQ ID NO: 28. In some embodiments, the mammalian cytokine includes IL-10.In some embodiments, the IL-10 comprises SEQ ID NO:25.

[0005] In some embodiments, the genus Propionibacterium includes a member selected from the group consisting of Propionibacterium acidifaciens, Propionibacterium acidipropionici, Propionibacterium acnes, Propionibacterium australiense, Propionibacterium avidum, Propionibacterium cyclohexanicum, Propionibacterium freudenreichii, Propionibacterium freudenreichii, Propionibacterium granulosum, Propionibacterium jensenii, Propionibacterium microaerobic microaerophilum), Propionibacterium propionicum, and Propionibacterium thoeniiand. In some embodiments, the strain of Propionibacterium acnes comprises a CRISPR (clustered regularly interspaced short palindromic repeats) array. In some embodiments, the strain of Propionibacterium acnes is Propionibacterium acnes, Type II, Ribosomal Type 6 (R6 Type IIP.acnes).

[0006] In some embodiments, nucleic acid comprises an inducible promoter configured to regulate the expression of mammalian growth factor or mammalian cytokine. In some embodiments, nucleic acid comprises an endogenous promoter configured to instruct the expression of mammalian growth factor or mammalian cytokine. In some embodiments, the expression of endogenous pathogenic proteins is significantly reduced or eliminated in one or more genetically modified bacteria. In some embodiments, endogenous pathogenic proteins include glyceraldehyde 3-phosphate dehydrogenase (GADPH) protein or CAMP2 protein. In some embodiments, one or more genetically modified bacteria include an inducible promoter for regulating the expression of essential proteins. In certain embodiments, essential proteins are suitable housekeeping genes. In certain embodiments, essential proteins are suitable chromosome replication initiation proteins. In some embodiments, the essential protein is selected from: chromosome replication initiation protein DnaA, FtsA, FtsI, FtsL, FtsK, FtsN, FtsQ, FtsW, FtsZ (e.g., filamentous temperature-sensitive growth, in some embodiments, the gene with FTS is an operon encoding a constriction ring that allows division), cell division protein (e.g., ZipA gene), shikimate 5-dehydrogenase (e.g., AROE, aroE gene), ATP synthase (e.g., ATP synthase, F1 complex, β subunit, e.g., atpD gene), guanylate kinase (e.g., gmk), GMP synthase (e.g., guaA), GTP binding protein (e.g., lepA), recombinase A protein (e.g., recA), superoxide dismutase (e.g., sodA gene). In some embodiments, the inducible promoter can be induced by sugar, e.g., by lactose or arabinose. In some embodiments, the inducible promoter can be induced by amino acids, e.g., by synthetic amino acids. In some embodiments, the composition is formulated for topical or mucosal administration to a mammal.

[0007] In certain embodiments, the genetically modified microorganism, such as a bacterium of the species Propionibacterium acnes, comprises multiple genetic modifications. In a specific aspect, the modified microorganism 1) expresses a mammalian growth factor, wherein the mammalian growth factor is secreted; 2) includes an inducible promoter that directs the expression of an essential protein, such as a chromosome replication initiation protein DnaA, FtsA, FtsI, FtsL, FtsK, FtsN, FtsQ, FtsW, FtsZ, ZipA, aroE, atpD, gmk, guaA, lepA, recA, or sodA); and 3) is modified such that the expression of endogenous CAMP2 and / or endogenous GADPH protein is significantly reduced or eliminated. In another specific aspect, a genetically modified microorganism, such as a bacterium of the species Propionibacterium acnes, comprises 1) a human cytokine, such as IL10, wherein the cytokine (e.g., IL10) is secreted; 2) includes an inducible promoter that directs the expression of an essential protein (e.g., an essential protein and / or a gene encoding an essential protein), such as a chromosomal replication initiator protein DnaA, FtsA, FtsI, FtsL, FtsK, FtsN, FtsQ, FtsW, FtsZ, ZipA, aroE, atpD, gmk, guaA, lepA, recA, orsodA; and 3) is modified such that the expression of endogenous CAMP2 and / or endogenous GADPH protein is significantly reduced or eliminated.

[0008] In certain embodiments, a composition comprises one or more genetically modified microorganisms, such as bacteria comprising Propionibacterium acnes species. In a specific aspect, a composition comprises 2, 3, 4, 5, 6, 7, 8, 9, 10 or more species of bacteria such as Propionibacterium acnes species, each of which is genetically modified in a different manner. For example, the first genetically modified microorganism of the composition can express cytokines, such as IL-10, IL-6, IL-7 or IL-8; and the second genetically modified microorganism of the composition can express growth factors, such as TGF-β, VEGF, HGF, FGF, IGF1, PDGF, GMCSF, EGF or HGH. Such a combination can include one or more genetically modified microorganisms, wherein the expression of endogenous pathogenic proteins, such as glyceraldehyde 3-phosphate dehydrogenase (GADPH) protein or CAMP2 protein, is significantly reduced or eliminated in one or more genetically modified bacteria. Such a combination can also include one or more genetically modified microorganisms, such microorganisms include an inducible promoter for regulating the expression of essential proteins, such as proteins selected from chromosome replication initiator proteins DnaA, FtsA, FtsI, FtsL, FtsK, FtsN, FtsQ, FtsW, FtsZ, ZipA, aroE, atpD, gmk, guaA, lepA, recA and sodA. Such a combination also includes genetically modified microorganisms, such as bacteria with multiple genetic modifications of Propionibacterium acnes species.

[0009] In some embodiments, the genetically modified microorganism, such as a bacterium of the species P. acnes, comprises an inducible promoter that regulates expression of an essential protein. In certain aspects, protein expression is induced or stimulated by the presence of a sugar or sugar analog, i.e., the promoter is induced by a sugar or sugar analog. BRIEF DESCRIPTION OF THE DRAWINGS

[0010] The accompanying drawings illustrate some embodiments of the present technology and are not limiting. For clarity and ease of illustration, the accompanying drawings are not drawn to scale, and in some cases, various aspects are shown exaggerated or enlarged to facilitate understanding of specific embodiments.

[0011] Figure 1 Shown is the plasmid map of dnaA-Bs-Cm: self-ligated DNA used to construct a growth-arrested strain of Bacillus subtilis.

[0012] Figure 2 The plasmid map of 18-araRE-ftsOp-erm is shown: plasmid used for the construction of a growth-arrested strain of P. acnes I, arabinose-inducible fts operon.

[0013] Figure 3The plasmid map of 18-bgalpro-dnaA-erm-cm is shown: plasmid used for construction of a growth-arrested strain of P. acnes II, lactose-inducible dnaA.

[0014] Figure 4A Shown is the plasmid map of the protein expression vector pET15-IL10: expression vector for IL-10.

[0015] Figure 4B The plasmid map of the protein expression vector pET15-EGF is shown: Expression vector for EGF.

[0016] Figure 4C The plasmid map of the protein expression vector pET15-GH is shown: Expression vector for GH.

[0017] Figure 5 Shown is the plasmid map of 18-CAMPII-erm-cm: plasmid used to construct CAMPII mutant P. acnes strains.

[0018] Figure 6 Shown is the plasmid map of β-gal pro-IL10: plasmid used for construction of lactose-inducible IL10-secreting P. acnes strain.

[0019] Figure 7 The plasmid map of 19-CAMPII-sig-IL10 is shown: plasmid used for construction of CAMPII mutants and IL-10 expressing strains of P. acnes.

[0020] Figure 8 Shown is the plasmid map of 19-sig-IL10-gapdh: a plasmid used for the construction of GAPDH mutant and IL-10 expressing strains of P. acnes.

[0021] Fig. 9 The scheme used to construct the untagged mutant constructs is shown.

[0022] Fig.10 Type II strains from Propionibacterium acnes (RecA ATCC 11828, SEQ ID NO: 274) and the RecA gene from a type I strain of Propionibacterium acnes (RecANCTC737, SEQ ID NO: 275). The shaded area indicates nucleotide base identity at the same base position. The numbers shown are relative to the position of the sequence in the full-length gene.

[0023] Fig.11 The RecA gene sequenced from the putative RT6 clone is shown. NCTC737, SEQ ID NO:277; NC_017_41_RecA, SEQ ID NO:278; NC_001_4_RecA, SEQ ID NO:279; NC_003_18_RecA, SEQ ID NO:280; NC_005_31_RecA, SEQ ID NO:281; NC_007_33_RecA, SEQ ID NO:282; NC_009_34_RecA, SEQ ID NO:283; NC_011_35_RecA, SEQ ID NO:284; NC_015_39_RecA, SEQ ID NO:285; NC_019_43_RecA, SEQ ID NO:286; NC_021_44_RecA, SEQ ID NO: 287; NC_023_45_RecA, SEQ ID NO: 288; NC_025_46_RecA, SEQ ID NO: 289) and the RecA gene from the ATTCC11828 strain (RecA 11828, SEQ ID NO: 276) region 720-1191. The shaded area indicates nucleotide base identity at the same base position.

[0024] Fig.12 The SNP sequence of 16S RNA of strain ATCC11828 of Propionibacterium acnes (SEQ ID NO: 290) was shown to be different from the SNP sequences isolated from the Propionibacterium acnes strains isolated in Example 1 (PA_001_4_16S, SEQ ID NO: 291; PA_002_18_16S, SEQ ID NO: 292; PA_003_20_16S, SEQ ID NO: 293; PA_005_31_16S, SEQ ID NO: 294; PA_007_33_16S, SEQ ID NO: 295; PA_008_34_16S, SEQ ID NO: 296; PA_009_35_16S, SEQ ID NO:297; PA_011_39_16S, SEQ ID NO:298; PA_013_43_16S, SEQ ID NO: 299; PA_014_44_16S, SEQ ID NO: 300; The shaded area indicates the nucleotide base identity at the same base position.

[0025] Fig.13 Expression of human IL-10 (lane 1, IL-10), human growth hormone (lane 2, GH) and human epidermal growth factor (lane 3, EGF) by individual genetically modified P. acnes strains in growth medium is shown. The indicated proteins are expressed under the direction of the inducible LacZ promoter.

[0026] Fig.14 The scheme for constructing a growth-arrested P. acnes mutant strain is shown. The DNA regions of the arabinose-inducible promoter and regulator were amplified from Bacillus subtilis, and a fragment of the fts operon was ligated downstream of the arabinose-inducible promoter. The plasmid was introduced into P. acnes for single crossover recombination to construct an arabinose-regulated growth-arrested strain.

[0027] Fig.15 A growth comparison of wild-type and growth-arrested mutant strains of P. acnes is shown. Wild-type and growth-arrested mutant strains of P. acnes were streaked onto modified enhanced Clostridium medium containing glucose (1%) and arabinose (1.5%) and incubated at 37°C under anaerobic conditions. Colony sizes of these strains were examined on days 6, 10, and 15.

[0028] Fig.16 The expression of IL-10 (lane 2) in the growth medium of the genetically modified P. acnes strain is shown after induction with 0.1 mM IPTG (isopropyl-β-D-thiogalactopyranoside) for 1.5 hours. The growth medium before induction is shown in lane 1. DETAILED DESCRIPTION

[0029] Unless otherwise indicated herein, the materials described in this section are not prior art to the claims in this application and are not admitted to be prior art by inclusion in this section.

[0030] Disclosed herein are genetically modified microorganisms and compositions comprising genetically modified microorganisms. Microorganisms (e.g., bacteria) can be genetically modified to express and / or secrete biomolecules that are beneficial to mammals. In certain embodiments, genetically modified bacteria are further modified to significantly reduce or eliminate the expression of harmful virulence factors (e.g., toxins or antigens). In some embodiments, the growth and viability of such genetically modified microorganisms can be controlled / regulated by introducing a nucleic acid comprising an inducible promoter, and the inducible promoter regulates the expression of proteins that are essential to the growth and / or survival of the modified microorganisms. In certain embodiments, compositions comprising such genetically modified microorganisms are formulated for topical delivery to the skin of mammals.

[0031] Microorganism or microorganism used herein can refer to microscopic organisms, unicellular organisms or multicellular organisms. Examples of microorganisms may include but are not limited to bacteria, archaea, protozoa and fungi. In certain embodiments, the microorganism is a bacterium.

[0032] As used herein, "genetically modified organism" may refer to an organism in which the genetic material of the organism has been altered using genetic engineering techniques. The term genetically modified also refers to multiple genetic modifications, for example. For example, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more genetic modifications, such as a microorganism having an exogenous gene introduced for expression of a protein and a modification (e.g., gene knockout) to reduce the expression of an endogenous (microorganism) gene encoding a pathogenic molecule (e.g., a pathogenic peptide or protein).

[0033] Microorganisms (e.g., bacteria, eubacteria, yeast, fungi) can be genetically modified to produce one or more proteins, produce biotherapeutics, alter metabolism, prevent overgrowth, and / or prevent the expression of biomolecules. In some embodiments, the genetically modified organism is a genetically modified microorganism. In some embodiments, the genetically modified organism is a genetically modified bacterium. In certain embodiments, the Propionibacterium acnes bacterium is genetically modified. It will be appreciated by those skilled in the art that there are a variety of ways to produce a genetically modified organism, such as by producing a gene knockout, by introducing a heterologous nucleic acid, and / or by producing a mutation.

[0034] In some embodiments, nucleic acid (for example, gene or its part) is introduced into microorganism using suitable technology.In some embodiments, microorganism is transformed with nucleic acid by suitable technology.The limiting examples of suitable technology for introducing nucleic acid into microorganism include electroporation, transduction (for example, by phage injection nucleic acid), microinjection, by induction ability (for example, by adding basic cation, cesium, lithium, polyethylene glycol or by osmotic shock) etc. or its combination.Nucleic acid can be introduced into microorganism in the form of for example linear or circular plasmid.In some embodiments, by using suitable selection method (for example selection marker) select the microorganism of transformation so that nucleic acid is integrated into the genome of microorganism.

[0035] Gene encoding specific protein, it realizes specific biochemical function in living microorganisms after being expressed by transcription and translation.Gene sometimes includes the DNA segment participating in the production of polypeptide chain, and sometimes includes the region (such as open reading frame) before and after the coding region participating in the transcription / translation of gene product and the regulation of transcription / translation.Essential gene is the endogenous gene (such as, endogenous for microorganism) producing microbial growth and / or necessary polypeptide (such as, essential protein).The limiting examples of the essential protein of bacterium include DnaA, FtsA, FtsI, FtsL, FtsK, FtsN, FtsQ, FtsW, FtsZ, ZipA, aroE, atpD, gmk, guaA, lepA, recA and sodA.

[0036] "Gene knockout" used herein refers to a combination of some genetic techniques that can make a specific gene inoperable or inactive. In some embodiments, gene knockout reduces or eliminates the expression of polypeptides from genes. In certain embodiments, the expression of genes is significantly reduced or eliminated. Significant reduction refers to when compared with the endogenous expression level of genes, the expression of genes is reduced by at least 80%, at least 90%, at least 95% or at least 98%. The expression of genes can be determined by suitable techniques (for example, by measuring transcripts or expressed protein levels). Any suitable technique can be used to produce gene knockouts in microorganisms (such as bacteria). Gene knockouts in microorganisms can be carried out by the following techniques: transposon mutagenesis, in vitro genetic engineering to modify genes included on plasmids or bacterial artificial chromosomes (BAC) and move the modified constructs to the organisms studied, homologous recombination in vivo and other techniques known to those skilled in the art. In certain embodiments, knockout genes are carried out by inactivating endogenous promoters, operators or regulatory elements necessary for transcription or translation of genes. In some embodiments, knockout genes are carried out by introducing one or more mutations that make the function of the protein expressed from the gene unable to be realized. In certain embodiments, the gene is partially or completely removed from the genome of the microorganism.In some embodiments, an endogenous gene is knocked out by replacing the gene with a different gene (e.g., a heterologous gene or a non-functional gene).

[0037] In some embodiments, microorganisms are genetically modified to prevent secretion of pathogenic molecules (e.g., pathogenic peptides or proteins). In some embodiments, pathogenic molecules are toxic molecules (e.g., toxins). In certain embodiments, genes encoding pathogenic molecules and / or toxic molecules are knocked out. In certain embodiments, bacteria are genetically modified to significantly reduce or eliminate the expression of pathogenic molecules or toxic molecules. Non-limiting examples of toxic molecules include bacterial endotoxins, bacterial exotoxins, and bacterial antigens. Bacterial antigens are any molecules (e.g., compounds or proteins) derived from bacteria that induce immune responses in mammals. In some embodiments, pathogenic molecules are Christie-Atkins-Munch-Petersen (CAMP) factors (e.g., CAMP factors of Propionibacterium acnes). In certain embodiments, one or more CAMP factors (e.g., CAMP1, CAMP2, CAMP3, CAMP4, and / or CAMP5) of Propionibacterium acnes are knocked out. In certain embodiments, Propionibacterium acnes bacteria are genetically modified to significantly reduce or eliminate the expression of one or more CAMP factors. In some embodiments, the pathogenic molecule is a bacterial glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (e.g., GAPDH of Propionibacterium acnes). In certain embodiments, one or more GAPDH genes of Propionibacterium acnes are knocked out. In certain embodiments, the Propionibacterium acnes bacteria are genetically modified to significantly reduce or eliminate the expression of GAPDH.

[0038] In some embodiments, the microorganism is genetically modified to produce an auxotrophic type. In some embodiments, the microorganism is genetically modified to prevent the acceptance of genetic material. In some embodiments, the microorganism is naturally modified or genetically modified to prevent the donation of genetic material. In some embodiments, the gene for the competent protein ComEA is modified to prevent the donation of genetic material. In some embodiments, the gene for the competent protein ComEA is modified to prevent the acceptance of genetic material. In some embodiments, the gene for the competent protein ComFA is modified to prevent the donation of genetic material. In some embodiments, the gene for the competent protein ComFA is modified to prevent the acceptance of genetic material. In some embodiments, the gene for the competent protein ComA is modified to prevent the donation of genetic material. In some embodiments, the gene for the competent protein ComA is modified to prevent the acceptance of genetic material. In some embodiments, the gene for the competent protein ComK is modified to prevent the donation of genetic material. In some embodiments, the gene for the competent protein ComK is modified to prevent the acceptance of genetic material. In certain embodiments, the microorganism comprises a CRISPR array, or a CRISPR array is introduced into a microorganism (e.g., bacteria) to prevent or reduce the acceptance of foreign genetic material from other microorganisms.

[0039] Genetic modification of microorganisms can also be carried out to introduce non-functional and non-harmful changes to the genome, wherein there is no harmful phenotype to the microorganism. "Genetic markers" as described herein refer to the non-functional sequences introduced in the genome to detect the presence of genetically modified organisms or microorganisms. Any suitable genetic marker can be incorporated into the genetically modified microorganism using suitable techniques. Genetic modification can be carried out so that genetically modified microorganisms are cataloged and distinguished from wild-type microorganisms, and in order to determine the presence of genetically modified microorganisms in the environment. Genetically modified microorganisms can be determined in the environment in the following ways: wiping a suspected genetically modified microorganism source, growing the microorganism in a minimal culture medium, obtaining genetic material, using qPCR with specific primers to the target sequence, and sequencing the DNA of the genetically modified microorganism. Using genetic modification to introduce specific genetic tags can enable people to catalog and determine the presence of genetically modified microorganisms on subjects in need. In addition, when the microorganism is no longer needed, the technology can enable people to determine that the genetically modified microorganism is not present in the environment. In some embodiments, the microorganism is genetically modified to carry a marker for determining the presence or absence of a genetically modified microorganism on the host. Markers used to determine proliferation of genetically modified bacteria can also be used to analyze the subject's microbial flora to ensure that the bacteria are balanced during treatment.

[0040] Genetically modified microorganisms can be used to secrete biomolecules (e.g., proteins) to treat conditions in subjects in need. Genetically modified microorganisms can be used to treat subjects in need with skin diseases. Genetically modified microorganisms carrying nucleic acids for controlled expression of peptides can be advantageous because they can move on the skin and penetrate deep into pores and follicles, allowing absorption of secreted biomolecules. Microorganisms can be formulated for, for example, general cosmetics and for general cosmetics.

[0041] In several embodiments described herein, genetically modified microorganisms can be used to treat subjects with genetic diseases. In several embodiments herein, genetically modified microorganisms can be used to treat subjects with gastric diseases. In several embodiments herein, genetically modified microorganisms can be used to treat subjects with autoimmune diseases. In several embodiments, genetically modified microorganisms can be used to treat subjects treated with anticoagulants. In several embodiments, genetically modified microorganisms can be used to treat subjects with hemophilia. Genetically modified microorganisms including nucleic acids for peptides for treatment can be used in combination to meet the needs of subjects in need. In some embodiments, a second genetically modified microorganism can be used to treat subjects in need. In some embodiments, a third genetically modified microorganism can be used to treat subjects in need. In some embodiments, more than three genetically modified microorganisms can be used to treat subjects in need.

[0042] In certain embodiments, the genetically modified microorganism comprises a nucleic acid (e.g., a gene), wherein the expression of the gene is regulated by a promoter. A promoter is usually introduced at a suitable position relative to the target gene. For example, a promoter (e.g., an inducible promoter) is usually located at the transcription start site 5' of the target gene. In certain embodiments, the nucleic acid includes a promoter and / or a regulatory element necessary for the expression of a promoter gene (e.g., a heterologous gene or an endogenous gene). The promoter can be an endogenous promoter, a heterologous promoter, or a combination thereof. In some embodiments, the promoter is a constitutive promoter (e.g., T7, SP6, T3, or any suitable constitutive promoter). In some embodiments, the microorganism is genetically altered to include a gene (e.g., a target gene, an essential gene) under the control of an inducible promoter. An inducible promoter is usually a nucleic acid sequence for instructing the conditional expression of a gene. An inducible promoter can be an endogenous promoter, a heterologous promoter, or a combination thereof. An inducible promoter can include an operator system. An inducible promoter is usually configured to regulate the expression of a gene (e.g., a target gene, an essential gene). In certain embodiments, the inducible promoter comprises one or more genes, regulatory elements and / or gene products (e.g., inducible systems). In some embodiments, the inducible promoter requires the presence of certain compounds, nutrients, amino acids, sugars, peptides, proteins, or conditions (e.g., light, oxygen, heat, cold) to induce gene activity (e.g., transcription). In certain embodiments, the inducible promoter comprises one or more repressor elements. In some embodiments, the inducible promoter (e.g., a promoter comprising a repressor element) requires the absence of certain compounds, nutrients, amino acids, sugars, peptides, proteins, or conditions to induce gene activity (e.g., transcription). Any suitable inducible promoter, system, or operon can be used to regulate the expression of a gene (e.g., an essential gene). Non-limiting examples of inducible promoters include lactose regulatory systems (e.g., lactose operon systems), sugar regulatory systems, metal regulatory systems, steroid regulatory systems, alcohol regulatory systems, IPTG induction systems, arabinose regulatory systems (e.g., arabinose operon systems, e.g., ARA operon promoters, pBAD, pARA, P ARA E. ARA E. ARA RP araE , parts thereof, combinations thereof, etc.), synthetic amino acid regulatory systems (see, for example, Rovner AJ, et al., (2015) Nature 518(7537):89-93), fructose repressor, tac promoter / operator (pTac), tryptophan promoter, PhoA promoter, recA promoter, proU promoter, cst-1 promoter, tetA promoter, cadA promoter, nar promoter, P LIn some embodiments, the promoter comprises a promoter, a cspA promoter, an analog or a combination thereof. In certain embodiments, the promoter comprises a Lac-Z (LacZ) promoter or a portion thereof. In some embodiments, the promoter comprises a Lac operon or a portion thereof. In some embodiments, the inducible promoter comprises an arabinose (ARA) operon promoter or a portion thereof. In certain embodiments, the inducible promoter comprises an arabinose promoter or a portion thereof. The arabinose promoter can be obtained from any suitable bacteria. In certain embodiments, the inducible promoter comprises an arabinose operon of Escherichia coli or Bacillus subtilis. In certain embodiments, the inducible promoter is activated by the presence of sugar or its analogs. Non-limiting examples of sugar and sugar analogs include lactose, arabinose (e.g., L-arabinose), glucose, sucrose, fructose, IPTG, etc.

[0043] In order to measure safety, the use of the microorganism for producing biomolecules can also be controlled. In some embodiments, the genetically modified microorganism is engineered to be an auxotrophic type, wherein the growth and / or survival of the microorganism depends on the essential nutrients present. In some embodiments, the composition herein comprises this essential nutrient. The auxotrophic type can be controlled by the consumption of the provided nutrients to prevent excessive growth of microorganisms, or remove the microorganism from the environment. For example, for the Trp auxotrophic type, the tryptophan supplied can be removed or exhausted to slow down microbial growth or completely remove the microorganism from the environment. In the case of the Lys auxotrophic type, for example, the lysine provided can be removed from the environment to slow down the growth of the Lys auxotrophic type or to be completely removed from the environment. In certain embodiments, the composition comprises amino acids, such as lysine (Lys) or tryptophan (Trp). In some embodiments, the nutrients provided can be applied to the activated topical composition as a compound, so that the microorganism is maintained in the environment as required.

[0044] Disclosed herein is a method for preparing a nucleic acid for controlled expression of a peptide for treatment. Gene transcripts for the peptide for treatment can be synthesized by standard molecular cloning techniques known to those skilled in the art, and can be used to transform microorganisms to carry encoded target gene transcripts. In certain embodiments, the inducible promoter comprises an operon. In some embodiments, the nucleic acid comprises an operon sequence. The operon can be used to control the expression of a gene transcript or for the expression of a peptide for treatment at the DNA level. In some embodiments, the operon is a lac operon. In some embodiments, the operon is a Trp operon. In some embodiments, the operon is a repressor operon. As described herein, a repressor operon refers to an operon controlled by a repressor or a DNA or RNA binding protein that can inhibit the expression of one or more genes by binding to an operon or an operon. In the lac operon, if there is a lactose level that can bind to the operon and inhibit RNA polymerase binding, the gene is turned off, thereby reducing the transcription of the target gene. The trp operon is also a repressor operon that works by a negative inhibitory feedback mechanism. The repressor of the trp operon is tryptophan, which can bind to the operon and prevent the transcription of the gene. By controlling the production of the target gene by the operon, the production level of the peptide for treatment can be controlled by providing a repressor molecule to the microorganism to control the level of the secreted biomolecule produced. In some embodiments, the expression of the peptide for treatment can be inhibited by adding a repressor molecule. In some embodiments, the repressor molecule is tryptophan. In some embodiments, the repressor molecule is lactose.

[0045] Biomolecules as described herein refer to any type of molecule produced by a living organism. Biomolecules may include, but are not limited to, macromolecules, proteins, sugars, polysaccharides, lipids, nucleic acids, peptides, metabolites, glycolipids, sterols, growth factors, hormones, glycerolipids, vitamins, neurotransmitters, metabolites, enzymes, monomers, oligomers, and polymers. Biomolecules can be produced by microorganisms. In certain embodiments, the target gene encodes a biomolecule. In several embodiments described herein, some methods are described in which genetically modified microorganisms secrete biomolecules. In several embodiments, some methods are described in which genetically modified microorganisms carry enzymes that catalyze the production of biomolecules. In several embodiments, some methods are described in which genetically modified microorganisms carry enzymes that catalyze the production of hyaluronic acid. In several embodiments, some methods are described in which genetically modified microorganisms carry enzymes that catalyze the production of melanin. Different types of biomolecules can be used to treat subjects in need. In some embodiments, subjects suffer from skin diseases, hereditary diseases, diseases, autoimmune diseases, gastropathy, aging damage, and hemophilia. In some embodiments, subjects or subjects in need suffer from acne.

[0046] In certain embodiments, the microorganism is genetically modified to express and / or secrete a growth factor. The growth factor can be a mammalian growth factor (e.g., a human growth factor).

[0047] Growth factors are naturally occurring biomolecules that can initiate and stimulate cell growth, causing cell conduction signals, proliferation, healing and cell differentiation. Growth factors can be proteins or peptides. In some embodiments, growth factors are hormones (e.g., mammalian hormones). In certain embodiments, bacteria are genetically modified by introducing nucleic acids encoding one or more growth factors (e.g., mammalian growth factors). Nucleic acids encoding growth factors may include: suitable promoters and / or regulatory elements for driving transcription and / or translation (e.g., expression) of growth factors, open reading frames encoding growth factors, and in some embodiments, suitable nucleic acids and / or peptide elements for instructing the secretion of microorganisms of growth factors. In certain embodiments, bacteria are genetically modified by introducing two or more nucleic acids encoding one or more growth factors (e.g., mammalian growth factors). In certain embodiments, bacteria are genetically modified by introducing nucleic acids instructing the expression of one or more growth factors (e.g., mammalian growth factors). In certain embodiments, bacteria are genetically modified to express and / or secrete growth factors (e.g., mammalian growth factors).

[0048] Several examples of growth factors include, but are not limited to, vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), adrenomedullin (AM), angiopoietin (Ang), autotaxin, bone morphogenetic protein (BMP), brain-derived neurotrophic factor (BDNF), epidermal growth factor (EGF), erythropoietin (EPO), fibroblast growth factor (FGF), glial cell line-derived neurotrophic factor (GDNF), granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), growth differentiation factor-9 (GDF9), healing factor, hepatocyte growth factor (HGF), hepatoma-derived growth factor (HGF), and mitochondrial growth factor (MGF). Factor (HDGF), insulin-like growth factor (IGF), migration stimulating factor, myostatin (GDF-8), nerve growth factor (NGF) and other neurotrophic factors, platelet-derived growth factor (PDGF), thrombopoietin (TPO), transforming growth factor (TGF-α), transforming growth factor β (TGF-β), tumor necrosis factor-α (TNF-α), vascular endothelial growth factor (VEGF), Wnt signaling pathway, placental growth factor (PGF), fetal bovine growth factor (FBS), IL-3 and IL-6 IL-1-cofactor, IL-2-T cell growth factor, IL-3, IL-4, IL-5, IL-6 and IL-7. In some embodiments, the genetically modified microorganism (e.g., bacteria) secretes growth factors.

[0049] Transforming growth factor β is a hormone that controls proliferation, differentiation and other functions in many cell types. Many cells synthesize TGFB1 and have specific receptors for it. It regulates many other growth factors both positively and negatively. It plays an important role in bone remodeling because it is an effective stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. In some embodiments, peptides for treatment include transforming growth factor β. TGFB can be used for general beauty, aging damage, general aging of tissues to cause younger skin by attracting fibroblasts and causing them to produce extracellular matrix, and resulting in thicker, younger skin. In some embodiments, transforming growth factor β includes SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68 or SEQ ID NO: 69.

[0050] Hepatocyte growth factor / scatter factor (HGF / SF) is a hormone for paracrine cell growth, motility and morphogenetic factors. It is secreted by mesenchymal cells and targets, and can act primarily on epithelial and endothelial cells, but also on hematopoietic progenitor cells. It has been shown to play a major role in embryonic organ development, particularly in myogenesis, in adult organ regeneration and wound healing.

[0051] For example, receptor tyrosine-protein kinase (MET) can transduce signals from the extracellular matrix to the cytoplasm by binding to hepatocyte growth factor / HGF ligands. This process can regulate many physiological processes, including proliferation, scattering, morphogenesis and survival. Ligand binding on the cell surface induces autophosphorylation of MET, providing docking sites for downstream signaling molecules on its intracellular domain. After being activated by the ligand, there is an interaction with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or adapter GAB1. Recruiting these downstream effectors by MET leads to the activation of several signaling cascades, including RAS-ERK, PI3 kinase-KKT or PLCγ-PKC cascades. RAS-ERK activation is associated with morphogenic effects, while PI3K / AKT coordinates pro-survival effects. During embryonic development, MET signaling plays a role in gastrulation, the development and migration of muscle and neuronal precursors, angiogenesis and kidney formation. In adults, the cascade is involved in wound healing, as well as organ regeneration and tissue remodeling.

[0052] Hepatocyte growth factor can be used for general cosmetology to induce younger skin by attracting fibroblasts and causing them to produce extracellular matrix, resulting in thicker, younger skin. This process can also promote differentiation and proliferation of hematopoietic cells. In some embodiments, the peptide used for treatment includes hepatocyte growth factor. In some embodiments, the hepatocyte growth factor includes SEQ ID NO: 70.

[0053] Vascular endothelial growth factor (VEGF) is a signaling protein produced by cells that stimulates vasculogenesis and angiogenesis. It is part of the system that restores oxygen supply to tissues when blood circulation is insufficient. The normal function of VEGF is to create new blood vessels during embryonic development, new blood vessels after injury, new muscles after exercise, and new blood vessels to bypass blocked blood vessels. VEGF can be used in general beauty to induce younger-looking skin by attracting fibroblasts and causing them to produce extracellular matrix, resulting in thicker, younger-looking skin.

[0054] VEGF-A is a growth factor active in angiogenesis, vascularization, and endothelial cell growth. VEGF-A induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis, and induces vascular permeabilization. VEGF-A binds to FLT1 / VEGFR1 and KDR / VEGFR2 receptors, heparin sulfate, and heparin. NRP1 / neuropilin-1 binds to isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR, but does not activate downstream signaling pathways, does not activate angiogenesis, and inhibits tumor growth. In some embodiments, the peptide used for treatment includes VEGF-A. In some embodiments, VEGF-A includes SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, or SEQ ID NO:87.

[0055] VEGF-B is a growth factor for endothelial cells. VEGF-B167 binds heparin and neuropilin-1, while the binding of neuropilin-1 to VEGF-B186 is regulated by proteolysis. In some embodiments, the peptide used for treatment includes VEGF-B. In some embodiments, VEGF-B includes SEQ ID NO: 88 or SEQ ID NO: 89.

[0056] VEGF-C is a growth factor with activity in angiogenesis and endothelial cell growth, stimulating their proliferation and migration, and also having an impact on the permeability of blood vessels. VEGF-C can play a role in the angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also plays a role in maintaining differentiated lymphatic endothelium in adults. VEGF-C can bind to and activate VEGFR-2 (KDR / FLK1) and VEGFR-3 (FLT4) receptors. In some embodiments, the peptide for treatment includes VEGF-C. In some embodiments, VEGF-C includes SEQ ID NO:90.

[0057] VEGF-D (c-Fos-induced growth factor or FIGF) is a growth factor active in angiogenesis, lymphangiogenesis, and endothelial cell growth, stimulating their proliferation and migration, and also having an effect on vascular permeability. VEGF-D can play a role in the formation of venous and lymphatic vasculature during embryogenesis, and also plays a role in maintaining differentiated lymphatic endothelium in adults. VEGF-D can bind to and activate VEGFR-2 (KDR / FLK1) and VEGFR-3 (FLT4) receptors. In some embodiments, the peptide used for treatment includes VEGF-D. In some embodiments, VEGF-D includes SEQ ID NO:91.

[0058] Placental growth factor (PGF) is a member of the VEGF family and can play a role in angiogenesis and vascularization during embryogenesis. PGF is active in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1 / VEGFR-1. The isoform PlGF-2 binds to NRP1 / neuropilin-1 and NRP2 / neuropilin-2 in a heparin-dependent manner. PFG can also promote cell tumor growth. PGF can be used for general beauty to cause younger skin by attracting fibroblasts and causing them to produce extracellular matrix, and leading to thicker, younger skin. In some embodiments, the peptide used for treatment includes PGF. In some embodiments, PGF includes SEQ ID NO:92.

[0059] Platelet-derived growth factor subunit A (PDGFA) plays an important role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis. PDGFA is an effective mitogen for cells of mesenchymal origin. PDGFA is required for normal alveolar septum formation during embryogenesis, normal development of the gastrointestinal tract, normal development of Leydig cells and spermatogenesis. PDGFA is required for normal oligodendrocyte development and normal myelination in the spinal cord and cerebellum. PDGFA plays an important role in wound healing. Transduction signals can also be regulated by forming heterodimers with PDGFB. PDGFA can be used for general beauty to cause younger skin by attracting fibroblasts and causing them to produce extracellular matrix, and leading to thicker, younger skin. In some embodiments, the peptide used for treatment includes PDGFA. In some embodiments, PDGFA includes SEQ ID NO:93 or SEQ ID NO:94.

[0060] Platelet-derived growth factor subunit B (PDGFB) plays an important role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis. PDGFB is a potent mitogen for cells of mesenchymal origin. PDGFB is required for the normal proliferation and recruitment of pericytes and vascular smooth muscle cells in the central nervous system, skin, lungs, heart and placenta. PDGFB is required for normal vascular development and normal development of glomeruli. PDGFB plays an important role in wound healing. Transduction signals can also be regulated by the formation of heterodimers by PDGFB and PDGFA. PDGFB can be used for general beauty to cause younger skin by attracting fibroblasts and causing them to produce extracellular matrix, resulting in thicker, younger skin. In some embodiments, peptides used for treatment include PDGFB. In some embodiments, PDGFB comprises SEQ ID NO:95 or SEQ ID NO:96.

[0061] Platelet-derived growth factor C (PDGFC) plays an important role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis. PDGFC is an effective mitogen and chemoattractant for cells of mesenchymal origin. PDGFC is required for normal bone formation during embryonic development, particularly for the normal development of craniofacial bones and the normal development of the palate. PDGFC is required for normal skin morphogenesis during embryonic development. PDGFC plays an important role in wound healing, in which it appears to involve three stages: inflammation, proliferation and remodeling. PDGFC plays an important role in angiogenesis and vascular development, and is involved in the fibrotic process, in which interstitial fibroblasts are transformed into myofibroblasts plus collagen deposition. The CUB domain of PDGFC has mitogenic activity in coronary artery smooth muscle cells, which indicates a role that exceeds the latency period of maintaining the PDGF domain. In the nucleus, PDGFC seems to have additional functions. PDGFC can be used for general beauty to cause younger skin by attracting fibroblasts and making them produce extracellular matrix, and leads to thicker, younger skin. In some embodiments, the peptide for use in treatment comprises PDGFC. In some embodiments, PDGFC comprises or SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99 or SEQ ID NO:100.

[0062] Platelet-derived growth factor D (PDGFD) plays an important role in the regulation of embryonic development, cell proliferation, cell migration, survival, and chemotaxis. PDGFD is a potent mitogen for cells of mesenchymal origin. PDGFD plays an important role in wound healing. PDGFD induces macrophage recruitment, increased interstitial pressure, and vascular maturation during angiogenesis. PDGFD can trigger the events leading to mesangial proliferative glomerulonephritis, including the influx of monocytes and macrophages and the production of extracellular matrix. PDGFD can be used in general cosmetology to cause younger-looking skin by attracting fibroblasts and causing them to produce extracellular matrix, resulting in thicker, younger-looking skin. In some embodiments, peptides used for treatment include PDGFD. In some embodiments, PDGFB includes SEQ ID NO:101 or SEQ ID NO:102.

[0063] The gene for epidermal growth factor (EGF) encodes a member of the epidermal growth factor superfamily. The encoded protein is synthesized as a large precursor molecule, which is proteolytically cleaved to produce a 53 amino acid epidermal growth factor peptide. This protein plays an important role in the growth, proliferation and differentiation of many cell types as a potent mitogenic factor. This protein exerts its effects by binding to a high affinity cell surface receptor, the epidermal growth factor receptor. Defects in this gene are the cause of type 4 hypomagnesemia. Disregulation of this gene is associated with the growth and progression of certain cancers. Alternative splicing results in multiple transcript variants and isoforms. Pro-EGF can be used in general cosmetology to cause younger skin by attracting fibroblasts and causing them to produce extracellular matrix, resulting in thicker, younger skin. In some embodiments, peptides used for treatment include Pro-EGF. Pro-EGF can have isoforms due to alternative splicing. In some embodiments, Pro-EGF includes SEQ ID NO: 103, SEQ ID NO:104, SEQ ID NO:105 or SEQ ID NO:106.

[0064] Fibroblast growth factor (FGF) plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. FGF can act as a potent mitogen in vitro. FGF can be used in general cosmetology to induce younger skin by attracting fibroblasts and causing them to produce extracellular matrix, resulting in thicker, younger skin. There are 22 different isoforms of FGF.

[0065] In some embodiments, the peptide for use in treatment comprises FGF1. In some embodiments, FGF1 comprises SEQ ID NO:107 or SEQ ID NO:108.

[0066] FGF2 has 4 isoforms produced by alternative initiation. FGF2 plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. FGF2 is an effective mitogen in vitro. In some embodiments, the peptide for treatment includes FGF2. In some embodiments, FGF2 includes SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111 or SEQ ID NO: 112.

[0067] FGF3 has 1 isoform and plays an important role in the regulation of embryonic development, cell proliferation and cell differentiation. FGF3 is required for normal ear development. In some embodiments, the peptide used for treatment includes FGF3. In some embodiments, FGF3 includes SEQ ID NO: 113.

[0068] FGF4 can have two isoforms due to alternative splicing. FGF4 plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. FGF4 can be used as an effective mitogen in vitro. In some embodiments, the peptides used for treatment include FGF4. In some embodiments, FGF4 comprises SEQ ID NO:114 or SEQ ID NO:115.

[0069] FGF5 can have two isoforms due to alternative splicing. FGF5 can play an important role in the regulation of cell proliferation and cell differentiation. FGF5 is required for normal regulation of hair growth cycle. FGF5 can play the role of an inhibitor of hair elongation by promoting the entry of the anagen phase (growth phase) into the catagen (apoptosis-induced catagen phase) from the anagen phase (growth phase) of the hair follicle. In some embodiments, the peptide for treatment includes FGF5. In some embodiments, FGF5 includes SEQ ID NO: 116 or SEQ ID NO: 117.

[0070] FGF6 isoforms play an important role in the regulation of cell proliferation, cell differentiation, angiogenesis and myogenesis, and are required for normal muscle regeneration. In some embodiments, the peptide for treatment includes FGF6. In some embodiments, FGF6 includes SEQ ID NO:118.

[0071] FGF7 (keratinocyte growth factor, KGF) has one isoform and plays an important role in the regulation of embryonic development, cell proliferation and cell differentiation. FGF7 is required for normal branching morphogenesis. This growth factor is particularly active on keratinocytes. FGF7 is a possible major paracrine effector of normal epithelial cell proliferation. In some embodiments, peptides for treatment include FGF7. In some embodiments, FGF7 includes SEQ ID NO:119.

[0072] FGF8 has four isoforms due to alternative splicing and plays an important role in the regulation of embryonic development, cell proliferation, cell differentiation, and cell migration. FGF8 is required for normal brain, eye, ear, and limb development during embryogenesis. FGF8 is required for normal development of the gonadotropin-releasing hormone (GnRH) neuronal system. In some embodiments, the peptide used for treatment includes FGF8. In some embodiments, FGF8 includes SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO:122 or SEQ ID NO:123.

[0073] FGF9 has a kind of isotype, and plays an important role in the regulation of embryonic development, cell proliferation, cell differentiation and cell migration.FGF9 has an effect in the growth and differentiation of glial cells during development, the repair and regeneration of the damage of brain tissue, the differentiation and survival of neuronal cells, and the growth stimulation of glioma.In some embodiments, the peptide for the treatment of includes FGF9.In some embodiments, FGF9 includes SEQ ID NO:124.

[0074] FGF10 (KGF2) has one isoform and plays an important role in the regulation of embryonic development, cell proliferation and cell differentiation. FGF10 is required for normal branching morphogenesis. FGF10 can play a role in wound healing. In some embodiments, the peptide used for treatment includes FGF10. In some embodiments, FGF10 includes SEQ ID NO: 125.

[0075] FGF11 has one isoform and is involved in nervous system development and function. In some embodiments, the peptide for treatment comprises FGF11. In some embodiments, FGF11 comprises SEQ ID NO:126.

[0076] FGF12 has two isoforms due to alternative splicing and is involved in the development and function of the nervous system. In some embodiments, the peptide for treatment includes FGF12. In some embodiments, FGF12 includes SEQ ID NO: 127 or SEQ ID NO: 128.

[0077] FGF13 has 5 isoforms produced by alternative splicing. FGF13 is a microtubule-binding protein that directly binds to tubulin and participates in the polymerization and stability of microtubules. Through its effect on microtubules, FGF13 can participate in the thinning of axons by negatively regulating axonal and leading process branches. FGF13 plays a key role in neuronal polarization and migration in the cerebral cortex and hippocampus. In some embodiments, peptides for treatment include FGF13. In some embodiments, FGF13 includes or SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132 or SEQ ID NO: 133.

[0078] FGF14 has two isoforms produced by alternative splicing and is involved in the development and function of the nervous system. In some embodiments, the peptide for treatment includes FGF14. In some embodiments, FGF14 includes SEQ ID NO: 134 or SEQ ID NO: 135.

[0079] FGF16 has one isoform and plays an important role in the regulation of embryonic development, cell proliferation and cell differentiation and is required for normal cardiomyocyte proliferation and cardiac development. In some embodiments, the peptide used for treatment includes FGF16. In some embodiments, FGF16 includes SEQ ID NO:136.

[0080] FGF17 has two isoforms due to alternative splicing and plays an important role in the regulation of embryonic development and as a signaling molecule in the induction and patterning of the embryonic brain. FGF17 is required for normal brain development. In some embodiments, peptides for treatment include FGF17. In some embodiments, FGF17 comprises SEQ ID NO:137 or SEQ ID NO:138.

[0081] FGF18 has one isoform and plays an important role in the regulation of cell proliferation, cell differentiation and cell migration. FGF18 is required for normal ossification and bone development. FGF18 stimulates the proliferation of liver and intestine. In some embodiments, the peptide used for treatment includes FGF18. In some embodiments, FGF18 includes SEQ ID NO:139.

[0082] FGF19 has one isoform and is involved in the inhibition of bile acid biosynthesis by downregulating the expression of CYP7A1 after positively regulating the JNK and ERK1 / 2 cascades. FGF19 stimulates glucose uptake in adipocytes. The activity of FGF19 requires the presence of KLB and FGFR4. In some embodiments, the peptide for treatment includes FGF19. In some embodiments, FGF19 includes SEQ ID NO: 140.

[0083] FGF20 has an isoform and acts as a neurotrophic factor that regulates central nervous system development and function. In some embodiments, the peptide for treatment includes FGF20. In some embodiments, FGF20 includes SEQ ID NO: 141.

[0084] FGF21 has one isoform and stimulates glucose uptake in differentiated adipocytes by inducing expression of the glucose transporter SLC2A1 / GLUT1 (but not SLC2A4 / GLUT4 expression). The activity of FGF21 requires the presence of KLB. In some embodiments, the peptide for treatment includes FGF21. In some embodiments, FGF21 includes SEQ ID NO: 142.

[0085] FGF22 has one isoform and plays a role in fasting response, glucose homeostasis, lipolysis and lipogenesis. FGF22 can stimulate cell proliferation in vitro and can participate in hair development. In some embodiments, cells that secrete FGF22 can be used to treat alopecia. In some embodiments, peptides for treatment include FGF22. In some embodiments, FGF22 includes SEQ ID NO:143.

[0086] FGF23 has an isoform and is a regulator of phosphate homeostasis. FGF23 inhibits tubular phosphate transport by reducing SLC34A1 levels, and can upregulate EGR1 expression when KL is present. FGF23 acts directly on the parathyroid gland to reduce PTH secretion. FGF23 is also a regulator of vitamin D metabolism, and can negatively regulate osteoblast differentiation and matrix mineralization. In some embodiments, peptides for treatment include FGF23. In some embodiments, FGF23 includes SEQ ID NO:144.

[0087] Hormones are a class of regulatory biochemical substances that are produced by glands in all organisms and transported to distant target organs through the circulatory system to coordinate their physiology, function and behavior. Hormones can serve as the main form of communication between different organs and tissues. Hormones regulate various physiological and behavioral activities, including digestion, metabolism, breathing, tissue function, sensory perception, sleep, perception, pressure, growth and development, movement and reproduction. In some embodiments, the peptides used for treatment include hormones. Hormones can be used by subjects suffering from diseases caused by low hormone production in subjects. In certain embodiments, bacteria are genetically modified by introducing nucleic acids encoding hormones (e.g., mammalian hormones). In certain embodiments, bacteria are genetically modified to express and / or secrete hormones (e.g., mammalian hormones). In certain embodiments, hormones are somatotropins. In certain embodiments, hormones are mammalian somatotropins. In certain embodiments, hormones are bovine somatotropins or human somatotropins. In certain embodiments, somatotropins are growth hormones (GH).

[0088] Somatotropin is a hormone that plays an important role in growth control. Its main role in stimulating body growth is to stimulate the liver and other tissues to secrete IGF-1. It stimulates the differentiation and proliferation of myoblasts. It also stimulates amino acid uptake and protein synthesis in muscle and other tissues. In some embodiments, the peptide used for treatment includes somatotropin. In some embodiments, somatotropin includes SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48 or SEQID NO:49. Somatotropin can be used by subjects with low human somatotropin (HGH) production or subjects with low testosterone production. In some embodiments, cells containing nucleic acids for expressing peptides include amino acid sequences for somatotropin. Since microorganisms can have the benefit of being able to enter the stratum corneum of the dermis and enter the pores, the skin will have a better and increased chance to absorb these topical applications, which is compared to the situation where the molecule itself is topically applied through a lotion or cream. One benefit of delivering microbially produced hormones to subjects in need is that this method reduces the risk of hormone exposure to other subjects. Because, in some embodiments, genetically modified microorganisms are often engineered to provide only essential nutrients to subjects in need thereof, delivery of microbially produced hormones to subjects in need thereof may be safer than other methods of providing topical hormones, which can often result in undesired transfer of the topical hormones to other subjects.

[0089] Anti-inflammatory agents are substances or therapeutic agents that reduce inflammation. Interleukins (ILs) are a group of cytokines that can act as signaling molecules and as anti-inflammatory agents. Anti-inflammatory agents can be used for subjects with inflammatory conditions (e.g., acne) in need. Microorganisms that secrete anti-inflammatory agents have advantages over creams containing anti-inflammatory agents because the microorganisms have the ability to enter the stratum corneum of the dermis and into the pores, thereby increasing the chance of absorbing these anti-inflammatory agents.

[0090] In some embodiments, microorganisms are genetically modified to express and / or secrete anti-inflammatory agents. In certain embodiments, anti-inflammatory agents are cytokines. In some embodiments, genetically modified microorganisms secrete cytokines. Non-limiting examples of cytokines include IL-4, IL-6, IL-7, IL-8, IL-10 and IL-13. In certain embodiments, by introducing nucleic acids encoding one or more cytokines (e.g., mammalian cytokines), bacteria are genetically modified. Nucleic acids encoding cytokines may include: suitable promoters and / or regulatory elements for driving transcription and / or translation (e.g., expression) of cytokines, open reading frames encoding cytokines, and in some embodiments, suitable nucleic acid acids and / or peptide elements for instructing the secretion of microorganisms of cytokines. In certain embodiments, by introducing two or more nucleic acids encoding two or more cytokines (e.g., mammalian cytokines), bacteria are genetically modified. In certain embodiments, by introducing nucleic acids instructing the expression of one or more cytokines (e.g., mammalian cytokines), bacteria are genetically modified. In certain embodiments, bacteria are genetically modified to express and / or secrete cytokines (e.g., mammalian cytokines).

[0091] Interleukin 4 (IL-4) can participate in at least several B cell activation processes as well as the activation processes of other cell types. It is a co-stimulator of DNA synthesis. It induces the expression of class II MHC molecules on resting B cells. It enhances the secretion and cell surface expression of IgE and IgG1. It also regulates the expression of low affinity Fc receptors for IgE (CD23) on lymphocytes and monocytes. In some embodiments, the peptide used for treatment includes interleukin 4 or a portion thereof. In some embodiments, interleukin 4 includes SEQ ID NO:24.

[0092] Interleukin 10 (IL-10) can inhibit the synthesis of many cytokines, including IFN-γ, IL-2, IL-3, TNF, and GM-CSF produced by activated macrophages and by helper T cells. In some embodiments, the peptide used for treatment includes interleukin 10 or a portion thereof. In some embodiments, interleukin 10 includes SEQ ID NO: 25.

[0093] Interleukin 13 (IL-13) is a cytokine that inhibits the production of inflammatory cytokines. Interleukin 13 and interleukin 2 (IL2) synergistically regulate interferon-γ synthesis. Interleukin 13 is key in regulating inflammation and immune responses. In some embodiments, the peptide used for treatment includes interleukin 13 or a portion thereof. In some embodiments, interleukin 13 includes SEQ ID NO: 26.

[0094] Interleukin-1 receptor type 2 (IL1R2) is a non-transduction signaling receptor for IL1A, IL1B, and IL1RN. IL1R2 reduces IL1B activity. In certain embodiments, bacteria are genetically modified to express and / or secrete IL1R2. IL1R2 can act as a decoy receptor by competitive binding to IL1B and preventing its binding to IL1R1. IL1R2 can also regulate cellular responses by non-transduction signaling association with IL1RAP after binding to IL1B. IL1R2 (membrane and secreted forms) preferentially binds IL1B and poorly binds IL1A and IL1RN. Secreted IL1R2 recruits secreted IL1RAP with high affinity; this complex formation can be the primary mechanism for neutralizing IL1B by secreted / soluble receptors. In some embodiments, the peptide used for treatment includes IL1R2 or a portion thereof. In some embodiments, interleukin 13 includes SEQ ID NO: 27 or SEQ ID NO: 28.

[0095] Hyaluronic acid or HA / hyaluronan is a biomolecule synthesized by a class of intrinsic membrane proteins called hyaluronan synthases, of which there are three types in vertebrates: HAS1, HAS2 and HAS3. It is an anionic glycosaminoglycan widely distributed throughout connective tissue, epithelial tissue and neural tissue. Hyaluronic acid is non-sulfated and is formed in the plasma membrane rather than the Golgi, and can be very large, with a molecular weight typically reaching millions (in KDa). One of the main components of the extracellular matrix, hyaluronic acid significantly promotes cell proliferation and migration, and can also be involved in the progression of some malignant tumors.

[0096] HAS1 catalyzes the addition of GlcNAc or GlcUA monosaccharides to nascent hyaluronic acid polymers. It is essential in hyaluronic acid synthesis because hyaluronic acid is the main component of most extracellular matrices, which have structural roles in tissue structure and regulate cell adhesion, migration and differentiation. HAS1 is one of the isozymes that catalyzes the reaction of adding GlcNAc or GlcUA monosaccharides to hyaluronic acid polymers. HAS1 is also able to catalyze the synthesis of chitosan oligosaccharides based on substrates. HAS2 catalyzes the addition of GlcNAc or GlcUA monosaccharides to nascent hyaluronic acid polymers. HAS2 is one of the isozymes that catalyze this reaction, and it is particularly responsible for the synthesis of high molecular weight hyaluronic acid. HAS2 is necessary for the transformation of endocardial cushion cells into interstitial cells, which is a key process in heart development. HAS2 can also play a role in angiogenesis. High molecular weight hyaluronic acid can also play a role in early contact inhibition, which is a process that stops cell growth when cells come into contact with each other or with the extracellular matrix. HAS3 catalyzes the addition of GlcNAc or GlcUA monosaccharides to nascent hyaluronic acid polymers.

[0097] As therapy, dry, scaly skin, also referred to as xerosis, such as xerosis caused by atopic dermatitis or eczema, can be treated with prescription skin lotions containing sodium hyaluronate as active ingredients. In several embodiments described herein, nucleic acids encoding hyaluronan synthase or portions thereof are provided. In several embodiments, cells can carry nucleic acids encoding hyaluronan synthase or portions thereof. In some embodiments, hyaluronan synthase includes HAS1 (SEQ ID NO: 1), HAS2 (SEQ ID NO: 2), HAS3 isoform 1 (SEQ ID NO: 3) or HAS3 isoform 2 (SEQ ID NO: 4). Hyaluronic acid can be used for general beauty, plumping the skin to reduce wrinkles. In some embodiments, cells carrying nucleic acids encoding hyaluronan synthase or portions thereof can result in the production of hyaluronic acid. In several embodiments, peptides for treatment can be used for general beauty. Since cells can proliferate and locate in pores and hair follicles, the absorption of hyaluronic acid is increased compared to lotions containing hyaluronic acid applied topically. In some embodiments, a topical formulation comprising cells having a nucleic acid encoding a hyaluronan synthase or a portion thereof is administered to a subject with Sjögren's disease in need thereof.

[0098] Elastin is the main structural protein of tissues such as the aorta and the nuchal ligament, which must expand rapidly and recover completely. Elastin is a molecular determinant of late arterial morphogenesis, and it can also stabilize arterial structure by regulating the proliferation and organization of vascular smooth muscle. Elastin can be used to promote skin elasticity because it can be easily absorbed by the skin. In some embodiments, the peptide used for treatment includes elastin or a portion thereof. Since microorganisms can have the benefit of having the ability to enter the stratum corneum of the dermis and enter the pores, the skin will have a better and increased chance of absorbing elastin from bacteria, which is compared with the topical application of elastin by lotions or creams.

[0099] In some embodiments, the elastin or a portion thereof comprises SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, or SEQ ID NO:17.

[0100] Collagen is the main structural protein of various connective tissues in animals. Collagen exists in fibrous tissue, tendons, ligaments, skin in the form of elongated fibrils, and is also abundant in cornea, cartilage, bone, blood vessels, intestines and intervertebral discs. Collagen is mainly produced by fibroblasts. Collagen consists of a triple helix consisting of two identical a1 chains and additional chains that may be different in chemical composition. The amino acid composition of collagen may have a high hydroxyproline content. In some embodiments, the peptides used for treatment include collagen or a portion thereof. Collagen can be absorbed by the skin to add to the extracellular matrix and increase the thickness of the dermis. Since microorganisms may have the benefit of having the ability to enter under the stratum corneum of the dermis and into the pores, the skin will have a better and increased chance of absorbing collagen from bacteria, compared to topical application of these molecules themselves by lotions or creams. In some embodiments, the peptide for use in therapy comprising collagen or a portion thereof comprises SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, or SEQ ID NO:23.

[0101] As described herein, coagulation factors refer to chemical and cellular components that can cause blood to coagulate or coagulate. Coagulation factors can be used externally by a subject with hemophilia in need, or by a subject under treatment with a blood thinner. Blood thinners can include fish oil, aspirin, antiplatelet drugs and other types of anticoagulants. Anticoagulants can include, but are not limited to, antithrombotic agents, fibrinolytic agents and thrombolytic agents.

[0102] Coagulation factor VIII is a member of the multicopper oxidase family. Coagulation factor VIII is a cofactor of factor IXa, which is activated by Ca +2 and phospholipids to convert factor X into the activated form Xa. Coagulation factor VIII is a coagulation cofactor that circulates bound to von Willebrand factor and is part of the intrinsic coagulation pathway. It is a macromolecular complex consisting of two independent entities, one of which causes hemophilia A when deficient and the other causes von Willebrand's disease when deficient. Hemophilia A is a disorder of blood coagulation characterized by the occurrence of a permanent bleeding tendency. In some embodiments, the peptide for treatment includes coagulation factor VIII. In some embodiments, coagulation factor VIII includes SEQ ID NO: 29 or SEQ ID NO: 30. In some embodiments, the peptide for treatment includes a coagulation factor VIII heavy chain in an isoform of 200 kDa. In some embodiments, a coagulation factor VIII heavy chain of 200 kDa includes SEQ ID NO: 31. In some embodiments, the peptide for treatment includes a coagulation factor VIII heavy chain in an isoform of 92 kDa. In some embodiments, a coagulation factor VIII heavy chain of 92 kDa includes SEQ ID NO: 32. In some embodiments, the peptide for treatment includes the coagulation factor VIII B chain. In some embodiments, the coagulation factor VIII B chain includes SEQ ID NO: 33. In some embodiments, the peptide for treatment includes the coagulation factor VIIIa light chain. In some embodiments, the coagulation factor VIIIa light chain includes SEQ ID NO: 34.

[0103] Factor IX is a vitamin K-dependent plasma protein that 2+ In some embodiments, the peptide used for treatment is factor IX. In some embodiments, factor IV includes SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38 or SEQ ID NO: 39.

[0104] Melanin in the skin is produced by melanocytes, which are found in the basal layer of the epidermis. Although humans generally have similar concentrations of melanocytes in their skin, melanocytes in some individuals and ethnic groups more or less frequently express the melanin-producing gene, thereby conferring greater or lesser concentrations of skin melanin.

[0105] Tyrosinase is an oxidase and is the rate-limiting enzyme that controls the production of melanin. Tyrosinase participates in the hydroxylation of monophenols and the conversion of ortho-diphenols into corresponding ortho-quinones. Ortho-quinone undergoes several reactions and eventually forms melanin. In some embodiments, the peptide for treatment is produced by tyrosinase or a fragment thereof. In some embodiments, the tyrosinase comprises SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43 or SEQ ID NO:44. In some embodiments, the cell may comprise, for example, a nucleic acid encoding tyrosinase or a fragment thereof. In some embodiments, microorganisms produce tyrosinase for enzymatic production of melanin. Since microorganisms may have the benefit of having the ability to enter the stratum corneum of the dermis and into the pores, the skin will have a better and increased chance of absorbing these topicals, compared to the topical application of these molecules themselves by lotions or creams. The production of melanin can be used for "sunless" tanning to increase the melanin of the subject.

[0106] Chemokines are a family of small cytokines secreted by cells as signaling molecules. The protein size classified as chemokines is small (8-10KDa in size), and has four conservative cysteine ​​residues in conservative positions, which form a conservative three-dimensional shape in chemokines. Chemokines can be considered as proinflammatory, and can be induced to recruit cells of the immune system to the site of infection during an immune response, while others are considered to be homeostasis, and participate in cell migration during the normal process of tissue maintenance or growth. Chemokines are present in all vertebrates, some viruses and some bacteria, but have not been described for other invertebrates. In some embodiments, peptides for treatment include chemokines.

[0107] Platelet basic protein (LA-PF4) belongs to the chemokine family. LA-PF4 stimulates DNA synthesis, mitosis, glycolysis, intracellular cAMP accumulation, prostaglandin E2 secretion, and the synthesis of hyaluronic acid and sulfated glycosaminoglycans. It also stimulates human synoviocytes to form and secrete plasminogen activator. NAP-2 is a ligand for CXCR1 and CXCR2, and NAP-2, NAP-2(73), NAP-2(74), NAP-2(1-66) and the most potent NAP-2(1-63) are chemoattractants and activators of neutrophils. TC-1 and TC-2 are antimicrobial proteins that are released from activated platelet alpha granules in vitro. CTAP-III(1-81) is more effective than CTAP-III in attenuating chemokine-induced neutrophil activation. LA-PF4 can be used for general cosmetic purposes to induce younger-looking skin by attracting fibroblasts and causing them to produce extracellular matrix, and resulting in thicker, younger-looking skin. In some embodiments, the peptide used for treatment includes platelet basic protein. In some embodiments, platelet basic protein includes SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61 or SEQ ID NO:62.

[0108] DNA repair enzymes are used to repair DNA damaged by reactive oxygen species, replication errors, exogenous damage caused by external factors such as UV rays, toxins, mutagenic chemicals, DNA intercalators, and viruses. There are several types of damage, these damages can be oxidation by bases, alkylation by bases, deamination, depurination, base mispairing, monoadduct damage, and diadduct damage. DNA repair enzymes can be used for anti-aging, as well as reversing DNA damage by sun damage / radiation.

[0109] Base excision repair (BER) is a mechanism for repairing damaged DNA during the cell cycle, removing small, non-helix-distorting base lesions from the genome. BER is very important because it removes damaged bases that can cause mutations or lead to DNA breaks through mispairing during replication. The process is initiated by DNA glycosylases, which can recognize and remove damaged or inappropriate bases, forming AP sites. The AP site is then cleaved by AP endonucleases, resulting in a single-strand break that can then be processed by a short or long repair process.

[0110] In some embodiments, the peptide for treatment includes a base excision repair (BER) enzyme. In some embodiments, the BER enzyme includes SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154 or SEQ ID NO: 155.

[0111] Direct reversal of DNA damage is another repair mechanism to restore damaged DNA. The formation of pyrimidine dimers is the main type of damage caused by UV light. The damage distorts the DNA double helix and blocks transcription or replication through the damaged site. In some embodiments, the peptide used for treatment includes an enzyme for directly reversing DNA damage. In some embodiments, the enzyme for directly reversing DNA damage includes SEQ ID NO: 156, SEQ ID NO: 157 or SEQ ID NO: 158.

[0112] DNA mismatch repair proteins are involved in the recognition and repair of nucleic acids with erroneous insertions, deletions, and misincorporated bases that may originate from DNA replication and recombination processes and from DNA damage. In some embodiments, the peptides used for treatment include enzymes for DNA mismatch repair. In some embodiments, the enzymes for DNA mismatch repair include SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167 or SEQ ID NO: 168.

[0113] Nucleotide excision repair (NER) is a DNA repair mechanism that removes DNA damage caused by ultraviolet light. Ultraviolet damage can lead to DNA adducts, which can be composed of thymine dimers and 6,4-photoproducts. NER protein recognition leads to the removal of damage that contains short single-stranded DNA fragments. The undamaged complementary sequence is then used as a template by DNA polymerase to synthesize a short complementary sequence, which is then connected by DNA ligase. In some embodiments, the peptide used for treatment includes an enzyme for nucleotide excision repair. In some embodiments, the enzyme used for nucleotide excision repair includes or SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, or SEQ ID NO:197.

[0114] DNA editing and processing involves the use of several types of nucleases and participates in DNA replication and repair. For example, DNase IV can remove 5' overhanging flaps in DNA repair and process the 5' end of Okazaki fragments in lagging strand DNA synthesis. During long plaque base excision repair, a direct physical interaction between this protein and AP endonuclease 1 enables coordinated loading of the proteins onto substrates, thus passing substrates from one enzyme to the other. This protein is a member of the XPG / RAD2 endonuclease family and is one of ten proteins essential for cell-free DNA replication.

[0115] MTMR15, also known as myotubularin-related protein, is a DNA endonuclease and exonuclease involved in the repair of DNA damage caused by cross-linking agents. FAN1 is recruited to sites of interstrand cross-link damage by interacting with the protein complex FANCI-FANCD2 complex. Together, these proteins promote interstrand cross-link repair in a manner that is strictly dependent on their ability to accumulate at or near sites of DNA damage and is dependent on monoubiquitination by the FANCI-FANCD2 complex.

[0116] DNase III or TREX1 is a major nuclear DNA-specific 3'-5' exonuclease widely distributed in proliferating and non-proliferating mammalian tissues. DNase III translocates to the nucleus during S phase following DNA damage by γ-irradiation or hydroxyurea. DNase III prefers single-stranded DNA in repair.

[0117] TREX2 encodes a 3' nuclease. The encoded protein can participate in double-strand DNA break repair and can interact with DNA polymerase δ. TREX2 can remove mismatched, modified, fragmented and normal nucleotides to generate 3' ends for subsequent steps in the DNA metabolic pathway.

[0118] EXO1 / HEX1 is a 803 amino acid human protein that functions in DNA replication, repair and recombination. EXO1 / HEX1 can participate in mismatch-triggered resection, which is guided by strand breaks located at the 5' or 3' end of the mismatch pair.

[0119] Aprataxin (APTX) is another protein involved in the editing and processing of DNA. APTX plays a role in single-strand DNA repair by removing DNA ends in the form of AMP after ligation by DNA ligase IV during non-homologous end joining.

[0120] SPO11 is an editing and processing nuclease endonuclease that functions during meiotic recombination. SPO11 generates double-strand breaks (DSBs) in DNA, an important step in the meiotic recombination process. In the absence of SPO11, the generation of DSBs cannot be initiated, which can lead to abnormal chromosome segregation, which in turn can result in aneuploid gametes.

[0121] Endonuclease V (ENDOV) is a nuclease that edits and processes nucleases, and is an endoribonuclease that specifically cuts inosine-containing RNA at the second phosphodiester bond 3' to inosine. ENDOV has a strong preference for single-stranded RNA (ssRNA) to double-stranded RNA (dsRNA). ENDOV cuts mRNA and tRNA containing inosine. ENDOV is also able to cut structurally specific dsRNA substrates containing specific sites 5'-IIUI-3' and 5'-UIUU-3'. Inosine is present in many RNAs after editing; the function of inosine-specific endoribonucleases remains unclear. Inosine may play a regulatory role in edited RNA, or it may participate in antiviral responses by removing over-edited long viral dsRNA genomes that have undergone A to I editing.

[0122] In some embodiments, the peptides used for treatment include editing and processing nucleases. In some embodiments, the enzymes used for editing and processing include SEQ ID NO: 198, SEQ ID NO: 199, SEQ ID NO: 200, SEQ ID NO: 201, SEQ ID NO: 202, SEQ ID NO: 203, SEQ ID NO: 204, or SEQ ID NO: 205.

[0123] Telomeres are regions at the ends of chromosomes that shorten during aging and cell division or mitosis. In order to repair the ends of chromosomes, an enzyme, telomerase, repairs the ends that may have the potential to repair age- or disease-related damage. Telomerase is a ribonucleoprotein that adds DNA sequence repeats to the 3' end of DNA in the telomeric region (the end of a eukaryotic chromosome). In some embodiments, the peptide for treatment includes telomerase or a portion thereof. In some embodiments, telomerase or a portion thereof comprises SEQ ID NO: 206, SEQ ID NO: 207, SEQ ID NO: 208 or SEQ ID NO: 209.

[0124] Protection of telomere protein 1 is encoded by POT1, which is a member of the telombin family and is involved in the maintenance of telomeres. POT1 works by binding to telomeric repeats at the ends of eukaryotic chromosomes, regulating telomere length and protecting chromosome ends from irregular recombination, instability, and abnormal chromosomal instability. In several embodiments, the peptide for treatment includes protection of telomere protein 1 or a portion thereof. In some embodiments, protection of telomere protein 1 or a portion thereof comprises SEQ ID NO: 210 or SEQ ID NO: 211.

[0125] In some embodiments, a method is described in which the peptide to be treated comprises a fusion protein. In some embodiments, the fusion protein may comprise a first protein sequence comprising an amino acid sequence of a protector of elastin, collagen, an anti-inflammatory agent, a coagulation factor, a hormone, platelet basic protein, transforming growth factor, hepatocyte growth factor, vascular endothelial growth factor, placental growth factor, platelet-derived growth factor, epidermal growth factor, fibroblast growth factor, DNA repair enzyme, telomerase, or telomerase protein 1. In some embodiments, the fusion protein is fused to a second protein, the second protein comprising an amino acid sequence of a protector of elastin, collagen, an anti-inflammatory agent, a coagulation factor, a hormone, platelet basic protein, transforming growth factor, hepatocyte growth factor, vascular endothelial growth factor, placental growth factor, platelet-derived growth factor, epidermal growth factor, fibroblast growth factor, DNA repair enzyme, telomerase, or telomerase protein 1, wherein the amino acid sequence of the second protein is not the amino acid sequence of the first protein. The fusion protein may have the additional benefit of introducing the second portion into a therapeutic peptide to treat a subject in need thereof.

[0126] In several embodiments described herein, the population of genetically modified bacteria is produced and / or derived from bacterial members from the genus Propionibacterium, Cornybacterium Staphyloccous, Streptococcus, Lactobacillus, and Lactococcus. In some embodiments, the genetically modified bacteria are derived from the genus Propionibacterium. Non-limiting examples of Propionibacterium species include Propionibacterium acidifaciens, Propionibacterium acidipropionici, Propionibacterium acnes, Propionibacterium australiense, Propionibacterium avidum, Propionibacterium cyclohexanicum, Propionibacterium freudenreichii, Propionibacterium freudenreichii, Propionibacterium granulosum, Propionibacterium jensenii, Propionibacterium microaerobic. microaerophilum), Propionibacterium propionicum, and Propionibacterium thoeniiand.

[0127] In some embodiments, the genetically modified bacteria are derived from the species of Propionibacterium acnes (P. acnes). The genetically modified bacteria can be derived from pathogenic or non-pathogenic strains of P. acnes. Recent studies have shown that there are certain strains of P. acnes associated with pathogenicity and other strains associated with healthy skin (Fitz-Gibbon, S., et al., (2013) Invest. Dermatol., 133 (9): 2152-60; Lomholt HB and Kilian M. (2010) PLoS One, 5 (8): e12277; McDowell A, et al., (2011) Microbiology 157 (Pt 7): 1990-2003). Among the types considered to be associated with healthy skin, type II, ribotype 6 strains appear to have the lowest correlation with acne. Type II P. acnes contains a CRISPR array that confers immunity to P. acnes-specific phages and mobile genetic elements (Bru¨ggemann H, et al., (2012) PLoS ONE 7(3): e34171). This seems to explain why these bacteria can be symbiotic in nature, as it cannot acquire pathogenic traits from other bacteria.

[0128] Genetically modified bacteria can be derived from any suitable microbial group of P.acnes, and its non-limiting examples include type I microbial group, type II microbial group, type III microbial group, type IV microbial group and type V microbial group.In certain embodiments, genetically modified bacteria are derived from the P.acnes strain of type I (e.g., IA or IB type) phenotype, the P.acnes strain of type II phenotype or the P.acnes strain of type III phenotype.Genetically modified bacteria can be derived from any suitable ribotype of P.acnes, and its non-limiting examples include ribosome RT1 to RT30.In certain embodiments, genetically modified bacteria are derived from the P.acnes of ribosome type RT1, RT2, RT3, RT4, RT5, RT6, RT7, RT8, RT9 or RT10.In certain embodiments, genetically modified bacteria are derived from the P.acnes of ribosome type RT2 or RT6.In certain embodiments, genetically modified bacteria are derived from the P.acnes of type II strain and ribosome RT2 or RT6.

[0129] In some embodiments, the genetically modified bacteria are derived from bacteria that contain a CRISPR (clustered regularly interspaced short palindromic repeat) locus, which is sometimes referred to as a CRISPR array (e.g., see Horvath and Barrangou (2010) Science 327:167-70; Makarova et al., (2011) Nat Rev Microbiol 9:467-77; and Bru¨ggemann H, et al., (2012) PLoS ONE 7(3):e34171). Without being limited by theory, CRISPR arrays in bacteria such as P. acnes have been shown to confer protective "immunity" against invading genetic elements (e.g., viruses, phages, and plasmids). Without being limited by theory, the presence of a CRISPR array can maintain the integrity of the genome of the genetically modified bacteria and prevent the introduction of foreign genetic elements from other pathogenic bacterial strains. Although it is believed that the CRISPR array protects bacteria from the introduction of foreign genetic elements from other bacteria, phages, and / or viruses, bacteria containing CRISPR arrays are susceptible to transformation, stable integration of transformed DNA, and integration of nucleic acids by homologous recombination. In some embodiments, the genetically modified bacteria contain an endogenous CRISPR array. For example, in some embodiments, the genetically modified bacteria are derived from the RT2 or RT6 ribotypes of P. acnes, each of which contains an endogenous CRISPR array. In some embodiments, the genetically modified bacteria include an exogenous CRISPR array introduced by genetic manipulation.

[0130] In some embodiments, the modified bacterial colony is produced by Propionibacterium acnes or its strain. In some embodiments, the converted bacterial colony is produced by Corynebacterium striatum. In some embodiments, the converted bacterial colony is produced by Staphylococcus epidermis. In some embodiments, the converted bacterial colony is produced by Streptococcus thermophilus. In some embodiments, the converted bacterial colony is produced by Lactobacillus acidophilus. In some embodiments, the converted bacterial colony is produced by Lactococcus lactis. In some embodiments, the converted bacterial colony is produced by Enterococcus (Enterrococci). In some embodiments, the converted bacterial colony is produced by Micrococci. In some embodiments, the converted bacterial colony is produced by Demodex. In some embodiments, the converted bacterial colony is produced by Malassezia. In some embodiments, the transformed bacterial colony is produced by non-pathogenic Escherichia coli. In some embodiments, the transformed bacterial colony is produced by the genus Acidovorax. The transformed bacterial colony is produced by the genus Acidovorax temperans. In some embodiments, the transformed bacterial colony is produced by the genus Acinetobacter. In some embodiments, the transformed bacterial colony is produced by Acinetobacter haemolyticus. In some embodiments, the transformed bacterial colony is produced by Acinetobacter johnsonii. In some embodiments, the transformed bacterial colony is produced by Acinetobacter junii. In some embodiments, the transformed bacterial colony is produced by Acinetobacter ursingii. In some embodiments, the transformed bacterial colony is produced by Actinomyces. In some embodiments, the transformed bacterial colony is produced by Actinomyces naeslundii. In some embodiments, the transformed bacterial population is produced by Actinomyces neuii. In some embodiments, the transformed bacterial population is produced by the genus Anaerococcus. In some embodiments, the transformed bacterial population is produced by Anaerococcus prevotii.In some embodiments, the transformed bacterial colony is produced by the genus Atopobium. In some embodiments, the transformed bacterial colony is produced by Atopobium vaginae. In some embodiments, the transformed bacterial colony is produced by the genus Brevibacterium. In some embodiments, the transformed bacterial colony is produced by Brevibacterium paucivorans. In some embodiments, the transformed bacterial colony is produced by Brevundimonas aurantiaca. In some embodiments, the transformed bacterial colony is produced by Brevundimonas aurantiaca. In some embodiments, the transformed bacterial colony is produced by Brevundimonas vesicularis. In some embodiments, the transformed bacterial colony is produced by the genus Candidatus Nostocoida. In some embodiments, the transformed bacterial colony is produced by Candidatus Nostocoida limicola. In some embodiments, the conversion bacterial colony is produced by the genus Corynebacterium. In some embodiments, the conversion bacterial colony is produced by crowded Corynebacterium (Corynebacterium accolens). In some embodiments, the conversion bacterial colony is produced by non-fermentation Corynebacterium (Corynebacterium afermentans). In some embodiments, the conversion bacterial colony is produced by Corynebacterium amycolatum (Corynebacterium amycolatum). In some embodiments, the conversion bacterial colony is produced by Corynebacterium appendicis (Corynebacterium appendicis). In some embodiments, the conversion bacterial colony is produced by Corynebacterium aurimucosum (Corynebacterium aurimucosum). In some embodiments, the conversion bacterial colony is produced by Corynebacterium coyleae (Corynebacterium coyleae). In some embodiments, the conversion bacterial colony is produced by Corynebacterium durum (Corynebacterium durum). In some embodiments, the conversion bacterial colony is produced by Corynebacterium glaucum (Corynebacterium glaucum). In some embodiments, the transformed bacterial population is produced from Corynebacterium glucuronolyticum.In some embodiments, the conversion bacteria colony is produced by imitating Corynebacterium imitans. In some embodiments, the conversion bacteria colony is produced by Corynebacterium jeikeium. In some embodiments, the conversion bacteria colony is produced by Corynebacterium kroppenstedtii. In some embodiments, the conversion bacteria colony is produced by Corynebacterium lipophiloflavum. In some embodiments, the conversion bacteria colony is produced by Corynebacterium matruchotii. In some embodiments, the conversion bacteria colony is produced by Corynebacterium minutissimum. In some embodiments, the conversion bacteria colony is produced from Corynebacterium mucifaciens. In some embodiments, the conversion bacteria colony is produced by Corynebacterium pseudodiphthericum. In some embodiments, the transformed bacterial colony is produced by Corynebacterium nigricans. In some embodiments, the transformed bacterial colony is produced by Corynebacterium pseudodiphthericum. In some embodiments, the transformed bacterial colony is produced by Corynebacterium simulans. In some embodiments, the transformed bacterial colony is produced by Corynebacterium singulare. In some embodiments, the transformed bacterial colony is produced by Corynebacterium sundsvallense. In some embodiments, the transformed bacterial colony is produced by Corynebacterium tuberculostearicum. In some embodiments, the transformed bacterial colony is produced by the genus Diaphorobacter, which produces flocculants. In some embodiments, the transformed bacterial colony is produced by Diaphorobacter nitroreducens, which produces nitrifying flocculants. In some embodiments, the transformed bacterial colony is produced by the genus Enhydrobacter. In some embodiments, the transformed bacterial population is produced from Enhydrobacter aerosaccus.In some embodiments, the conversion bacterial colony is produced by the genus Enterobacter. In some embodiments, the conversion bacterial colony is produced by Enterobacter asburiae. In some embodiments, the conversion bacterial colony is produced by the genus Enterococcus. In some embodiments, the conversion bacterial colony is produced by Enterococcus faecalis. In some embodiments, the conversion bacterial colony is produced by Eremococcus. In some embodiments, the conversion bacterial colony is produced by Eremococcus coleocola. In some embodiments, the conversion bacterial colony is produced by Facklamia. In some embodiments, the conversion bacterial colony is produced by Facklamia hominis. In some embodiments, the conversion bacterial colony is produced by Facklamia languida. In some embodiments, the conversion bacterial colony is produced by Gardnerella. In some embodiments, the transformed bacterial colony is produced by Gardnerella vaginalis. In some embodiments, the transformed bacterial colony is produced by the genus Gemella. In some embodiments, the transformed bacterial colony is produced by Gemella haemolysans. In some embodiments, the transformed bacterial colony is produced by Gemella morbillorum. In some embodiments, the transformed bacterial colony is produced by Gemella sanguinis. In some embodiments, the transformed bacterial colony is produced by Gordonia. In some embodiments, the transformed bacterial population is produced by Gordonia bronchii. In some embodiments, the transformed bacterial population is produced by Gordonia sputi. In some embodiments, the transformed bacterial population is produced by Gordonia terrae. In some embodiments, the transformed bacterial population is produced by Streptomyces granulosus. In some embodiments, the transformed bacterial population is produced by Granulicatella elegans. In some embodiments, the transformed bacterial population is produced by Hyphomicrobium. In some embodiments, the transformed bacterial population is produced by Hyphomicrobium facile. In some embodiments, the transformed bacterial population is produced by Janibacter. In some embodiments, the transformed bacterial population is produced by Janibactermelonis. In some embodiments, the transformed bacterial population is produced by Kocuria. In some embodiments, the transformed bacterial population is produced by Kocuria marina. In some embodiments, the transformed bacterial population is produced by Kocuria palustris. In some embodiments, the transformed bacterial population is produced by Kocuria rhizophila. In some embodiments, the transformed bacterial population is produced by Lactobacillus. In some embodiments, the conversion bacterial colony is produced by Lactobacillus crispatus. In some embodiments, the conversion bacterial colony is produced by Lactobacillus jensenii. In some embodiments, the conversion bacterial colony is produced by Leuconostoc. In some embodiments, the conversion bacterial colony is produced by Leuconostoc argentinum. In some embodiments, the conversion bacterial colony is produced by Methylobacterium. In some embodiments, the conversion bacterial colony is produced by Methylobacterium extorquens. In some embodiments, the conversion bacterial colony is produced by Methylobacterium mesophilicum. In some embodiments, the conversion bacterial colony is produced by Micrococcus. In some embodiments, the conversion bacterial colony is produced by Micrococcus luteus. In some embodiments, the conversion bacterial colony is produced by Microlunatus. In some embodiments, the transformed bacterial population is produced from Microlunatus phosphovorus. In some embodiments, the transformed bacterial population is produced from the genus Mobiluncus curtisii.In some embodiments, the transformed bacterial colony is produced by Mobiluncuscurtisii subsp.holmesii. In some embodiments, the transformed bacterial colony is produced by the genus Mycobacterium. In some embodiments, the transformed bacterial colony is produced by Mycobacterium chlorophenolicum. In some embodiments, the transformed bacterial colony is produced by Mycobacterium obuense. In some embodiments, the transformed bacterial colony is produced by the genus Nakamurella. In some embodiments, the transformed bacterial colony is produced by Nakamurella multipartita. In some embodiments, the transformed bacterial colony is produced by the genus Pedomicrobium. In some embodiments, the transformed bacterial colony is produced by Pedomicrobium australicum. In some embodiments, the transformed bacterial colony is produced by the genus Peptoniphilus. In some embodiments, the conversion bacterial colony is produced from Peptoniphilus harei. In some embodiments, the conversion bacterial colony is produced by Peptostreptococcus. In some embodiments, the conversion bacterial colony is produced by Peptostreptococcus anaerobius. In some embodiments, the conversion bacterial colony is produced by Prevotella. In some embodiments, the conversion bacterial colony is produced by Prevotella bivia. In some embodiments, the conversion bacterial colony is produced by Prevotella corporis. In some embodiments, the conversion bacterial colony is produced by Prevotella disiens. In some embodiments, the conversion bacterial colony is produced by Prevotella melaninogenica. In some embodiments, the conversion bacterial colony is produced by Propionibacterium. In some embodiments, the transformed bacterial population is produced by Propionibacterium acnes. In some embodiments, the transformed bacterial population is produced by Propionibacterium granulosum. In some embodiments, the transformed bacterial population is produced by Pseudomonas.In some embodiments, the transformed bacterial colony is produced by Pseudomonas aeruginosa. In some embodiments, the transformed bacterial colony is produced by Pseudomonas saccharophila. In some embodiments, the transformed bacterial colony is produced by Pseudomonas stutzeri. In some embodiments, the transformed bacterial colony is produced by Pseudomonas tremae. In some embodiments, the transformed bacterial colony is produced by Rhodococcus. In some embodiments, the transformed bacterial colony is produced by Rhodococcus corynebacterioides. In some embodiments, the transformed bacterial colony is produced by Rhodococcus erythropolis. In some embodiments, the transformed bacterial colony is produced by Rothia. In some embodiments, the transformed bacterial colony is produced by Rothia aeria. In some embodiments, the transformed bacterial population is produced by Rothia dentocariosa. In some embodiments, the transformed bacterial population is produced by Rothiamucilaginosa. In some embodiments, the transformed bacterial population is produced by Rothianasimurium. In some embodiments, the transformed bacterial population is produced by Serratia. In some embodiments, the transformed bacterial population is produced by lipase-producing bacteria (Serratia liquefaciens). In some embodiments, the transformed bacterial population is produced by Serratia marcescenssubsp.Sakuensis. In some embodiments, the transformed bacterial population is produced by Sphingobium. In some embodiments, the transformed bacterial population is produced by Sphingobium amiens. In some embodiments, the transformed bacterial population is produced by Staphylococcus. In some embodiments, the transformed bacterial population is produced by Staphylococcus capitis. In some embodiments, the transformed bacterial population is produced by Staphylococcus caprae. In some embodiments, the transformed bacterial population is produced by Staphylococcus cohnii.In some embodiments, the conversion bacterial colony is produced by Staphylococcus epidermidis. In some embodiments, the conversion bacterial colony is produced by Staphylococcus haemolyticus. In some embodiments, the conversion bacterial colony is produced by Staphylococcus hominis. In some embodiments, the conversion bacterial colony is produced by Staphylococcus saccharolyticus. In some embodiments, the conversion bacterial colony is produced by Staphylococcus warneri. In some embodiments, the conversion bacterial colony is generated by Stenotrophomonas. In some embodiments, the conversion bacterial colony is produced by Stenotrophomonas maltophilia. In some embodiments, the conversion bacterial colony is produced by Streptococcus. In some embodiments, the conversion bacterial colony is produced by Streptococcus agalactiae. In some embodiments, the conversion bacterial colony is produced by Streptococcus cristatus. In some embodiments, the conversion bacterial colony is produced by Staphylococcus gordonii. In some embodiments, the conversion bacterial colony is produced by Streptococcus infantis. In some embodiments, the conversion bacterial colony is produced by Streptococcus intermedius. In some embodiments, the conversion bacterial colony is produced by Streptococcus mitis. In some embodiments, the conversion bacterial colony is produced by Streptococcus parasanguinis. In some embodiments, the conversion bacterial colony is produced by Streptococcus parasanguinis. In some embodiments, the conversion bacterial colony is produced by Streptococcus salivarius. In some embodiments, the conversion bacterial colony is produced by Streptococcus sanguinis. In some embodiments, the transformed bacterial population is produced from the genus Tetrasphaera. In some embodiments, the transformed bacterial population is produced from Tetrasphaera elongata.In some embodiments, the transformed bacterial colony is produced by the genus Tsukamurella. In some embodiments, the transformed bacterial colony is produced by Tsukamurella tyrosinosolvens. In some embodiments, the transformed bacterial colony is produced by the genus Tsukamurella. In some embodiments, the transformed bacterial colony is produced by the genus Veillonella. In some embodiments, the transformed bacterial colony is produced by the genus Veillonella. In some embodiments, the transformed bacterial colony is produced by Veillonella parvula. In some embodiments, the transformed bacterial colony is produced by Veillonella parvula. In some embodiments, the transformed bacterial colony is produced by Bradyrhizobiaceae U8776. In some embodiments, the transformed bacterial colony is produced by Carnobacterium AJ427446. In some embodiments, the transformed bacterial colony is produced by Corynebacterium AY581888. In some embodiments, the transformed bacterial colony is produced by Corynebacterium AF543288. In some embodiments, the transformed bacterial colony is produced by Corynebacterium X81872. In some embodiments, the transformed bacterial colony is produced by Corynebacterium X84253. In some embodiments, the transformed bacterial colony is produced by Dermacoccus AF409025. In some embodiments, the transformed bacterial colony is produced by Finegoldia AB109769. In some embodiments, the transformed bacterial colony is produced by Haemophilus AF224309. In some embodiments, the transformed bacterial population is produced from Methylobacterium AY741717. Neisseria DQ409137.

[0131] Bacterial strains are modified to avoid reactions, inflammation, methods for easy removal of bacteria, attenuation of bacteria, and prevent the release of harmful bacterial biomolecules that can be harmful to the host.

[0132] In some bacteria, there are toxic proteins that participate in lysis and inflammation. Bacteria can, for example, secrete toxins, such as endotoxins and exotoxins. Endotoxins are cell-associated substances that are structural components of bacteria and are released from bacteria or from bacterial cells caused by lysis according to host defense mechanisms. Exotoxins are secreted by bacteria and can be small biomolecules, proteins, and can also be the smallest peptides that can act enzymatically. Several examples of bacterial toxins include, but are not limited to, hemolysin (E. coli), alpha toxin (Staphylococcus aureus (S. aureus)), leukocidin (S. aureus), CAMP factor (Propionibacterium (Priopionibacterium)), hyaluronidase (Priopionibacterium), neuraminidase (Priopionibacterium), enterotoxin B (S. aureus), verotoxin (E. coli). For example, Propionibacterium acnes naturally produces the biomolecule CAMP factor, which has co-hemolytic activity with sphingomyelinase, which can impart cytotoxicity to keratinocytes and macrophages. CAMP factor, together with acid sphingomyelinase from host cells, can cause lysis and inflammation in the host. In another example, hemolysis is a mechanism used by many bacterial pathogens, which act to degrade, invade host cells and resist the host's immune system. Propionibacterium acnes carries 5 different CAMP homologues (CAMP1, CAMP2, CAMP3, CAMP4 and CAMP5) in its genome. Many other types of bacteria can also secrete cytotoxins. For example, Staphylococcus aureus can produce a variety of virulence factors, including but not limited to enzymes, toxins, superantigens, exfoliative toxins, alpha toxins, beta toxins, delta toxins and several types of two-component toxins.

[0133] In some bacteria, lipases may be used to obtain a beneficial effect. In some microorganisms, the gene for lipase is not knocked out because lipases can be used to break down oils in subjects with armpit odor or foot odor. In some embodiments, Propionibacterium is engineered to release lipases to reduce sebum secretion.

[0134] In order to prevent the harmful effects of virulence factors, modifications can be made to knock out the relevant specific genes involved in the secretion of bacterial virulence factors to produce conditional mutants. Conditional mutants can be described as having a wild-type phenotype under certain permissive environmental conditions and a mutant phenotype under other restrictive conditions. In some embodiments, genes encoding toxic proteins will mutate or be knocked out to prevent nosocomial infection or disease symptoms in the host. In some embodiments, genes encoding enzymes that cause host inflammation will mutate or be knocked out to prevent the manifestation of diseases in the host. In some embodiments, genes encoding proteins involved in the synthesis of host viral factors will mutate or be knocked out in bacteria. In some embodiments, the gene is used for CAMP factor. In some embodiments, the gene is used for lipase. However, in some microorganisms, the gene for lipase is not knocked out because lipase can be used to decompose the oil of subjects with armpit odor or sole odor. In some embodiments, Propionibacterium is engineered to release lipase, thereby reducing sebum secretion. In some embodiments, the gene is used for alpha toxin. In some embodiments, the gene is used for beta toxin. In some embodiments, the gene is used for delta toxin. In some embodiments, the gene is used for the type of two-component toxin. In some embodiments, the gene is for hemolysin.

[0135] Several microorganisms do not require any growth factors and can synthesize essential purines, pyrimidines, amino acids and vitamins, where they can start from a carbon source that is part of their own metabolism. However, some types of microorganisms will require purines, pyrimidines, amino acids and vitamins to grow, and must be added in the culture medium to allow these microorganisms to grow. By genetically modifying microorganisms so that they require growth factors that are not required by the wild type, those skilled in the art can produce genetically modified "auxotrophic" or mutant organisms with nutritional requirements that are not shared by the parent organism.

[0136] Genetically modified microorganisms can be modified so that they are auxotrophic. In order to generate dependence on its surrounding environment so as to survive, the amount of the microorganism in the microenvironment can be controlled, or the microbial population can be eliminated by exhausting the essential nutrients in the environment. In some embodiments, the microorganism comprises a genome with a mutation or knocks out a gene encoding glutamine synthetase. In some embodiments, the microorganism comprises a genome with a mutation or knocks out a gene encoding asparagine synthetase. In some embodiments, the microorganism comprises a genome with a mutation or knocks out a gene encoding aspartate kinase. In some embodiments, the microorganism comprises a genome with a mutation or knocks out a gene encoding aspartate semialdehyde dehydrogenase.

[0137] Toxins are also secreted by many fungi, so that they can successfully settle and infect the host under induction conditions. Secreted proteins can be related to the toxicity of several fungal species. For example, hydrolase production (which also plays a role in the pathogenicity of bacteria and yeast) is usually related to toxicity. Several toxins of fungi include but are not limited to secreted aspirinase (Sap) (Candida albicans (C.albicans)), phospholipase B enzyme (C.albicans), lipase (C.albicans). In order to prevent infection by fungi, specific genes can be mutated or knocked out to prevent toxic factors from causing disease in the host.

[0138] Fungal cells can be genetically engineered to secrete biomolecules. In several embodiments described herein, the transformed fungal cell colony is produced by a member from the group consisting of the genus. In several embodiments described herein, the transformed bacterial colony is produced by a bacterial member from the group consisting of the genus Candida. In several embodiments described herein, the transformed bacterial colony is produced by a bacterial member from Candida albicans, Candida glabrata, Candida tropicalis, Candida parapsilosis and Candida krusei.

[0139] In certain embodiments, the composition comprises one or more genetically modified microorganisms. In some embodiments, the composition comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9 or at least 10 genetically modified microorganisms. In some embodiments, the composition comprises 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more genetically modified microorganisms. In certain embodiments, the genetically modified microorganism in the composition is configured to express one or more target genes. In certain embodiments, the composition comprises a genetically modified microorganism, thereby significantly reducing or eliminating the expression of pathogenic molecules (for example, pathogenic proteins that are endogenous to microorganisms). In some embodiments, the composition comprises a genetically modified microorganism, wherein one or more genes of the microorganism (for example, endogenous essential genes) are knocked out. In some embodiments, the composition comprises a genetically modified microorganism, which is configured to express one or more essential genes under the guidance of an inducible promoter.

[0140] In certain embodiments, the composition comprises a pharmaceutically acceptable excipient or carrier. Pharmaceutically acceptable excipients or carriers considered for use herein are generally nontoxic to genetically modified microorganisms. Therefore, the pharmaceutical composition used according to the present invention can be formulated in a suitable manner using one or more physiologically acceptable carriers, which include excipients and adjuvants that can be used pharmaceutically. Suitable formulations can be determined according to the selected route of administration. In particular, suitable formulations, ingredients, excipients, etc. or combinations thereof as listed in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, 18th edition, 1990 can be used together with the compositions described herein. The compositions herein can be incorporated into or used with suitable materials described in Remington's.

[0141] As used herein, the terms "pharmaceutically acceptable" and "physiologically acceptable" refer to biologically acceptable formulations suitable for one or more routes of administration (in vivo delivery or contact), which are gaseous, liquid or solid or mixed states thereof. Such formulations include solvents (aqueous or non-aqueous), solutions (aqueous or non-aqueous), emulsions (e.g., oil-in-water or water-in-oil), suspensions, syrups, elixirs, dispersions and suspension media, coatings, isotonic and absorption-promoting or delayed agents compatible with drug administration or in vivo contact or delivery. Aqueous and non-aqueous solvents, solutions and suspensions may include suspending agents and thickening agents. Such pharmaceutically acceptable carriers include tablets (coated or uncoated), capsules (hard or soft), microbeads, powders, granules and crystals. Supplementary active compounds (e.g., preservatives, antibacterial agents, antiviral agents and antifungal agents) may also be incorporated into the composition.

[0142] Genetically engineered microorganisms can be placed in excipients that are optimal for survival of bacteria or fungi. In several embodiments described herein, compositions comprising carriers or excipients that help maintain the integrity and viability of bacteria are described. Carriers as described herein may refer to substances that have no therapeutic value for transporting active drugs for administration. Drug carriers as described herein may refer to carriers or inert media used as solvents in which pharmaceutically active agents are formulated and / or administered. Carriers may include polymeric micelles, liposomes, lipoprotein-based carriers, nanoparticle carriers, dendrimers, and other bacterial carriers known to those skilled in the art. Ideal carriers may be non-toxic, biocompatible, non-immunogenic, biodegradable, and may avoid being recognized by the host's defense mechanisms. In several embodiments described herein, compositions comprising carriers or excipients that help maintain the integrity of fungi are described. In some embodiments, the carrier is a drug carrier. In some embodiments, the drug carrier comprises a pharmaceutical composition. In some embodiments, the carrier is a polymeric micelle. In some embodiments, the carrier is a liposome. In some embodiments, the carrier is a lipoprotein-based carrier. In some embodiments, the carrier is a nanoparticle carrier. In some embodiments, the carrier is a dendrimer.

[0143] The pharmaceutical composition can be formulated to be compatible with a particular route of administration. Thus, the pharmaceutical composition includes carriers, diluents or excipients suitable for administration by various routes.

[0144] In some embodiments, the composition is formulated as, for example, a topical (e.g., skin) preparation. In some embodiments, the composition is formulated, for example, for topical administration to a mammal. Topical preparations may include, for example, gel preparations, cream preparations, lotion preparations, paste preparations, ointment preparations, oil preparations, and foam preparations. The composition may also include, for example, an absorption softener.

[0145] Other examples of compositions may optionally be formulated for delivery to mucosal membranes, or by inhalation, respiration, intranasal, oral, buccal, or sublingual delivery.

[0146] Salts may be added. Non-limiting examples of salts include acetate, benzoate, benzenesulfonate, bitartrate, bromide, carbonate, chloride, citrate, edetate, edisylate, etopate, fumarate, glucoheptonate, gluconate, hydrobromide, hydrochloride, iodide, lactate, lactobionate, malate, maleate, mandelate, methanesulfonate, methyl bromide, methylsulfate, mucate, naphthenate, nitrate, pamoate (pamoate), phosphate, diphosphate, salicylate and disalicylate, stearate, succinate, sulfate, tartrate, toluenesulfonate, triethyl iodide, valerate, aluminum, benzathine, calcium, ethylenediamine, lysine, magnesium, meglumine, potassium, procaine, sodium, tromethamine, or zinc.

[0147] Chelating agents may be added. Non-limiting examples of chelating agents include ethylenediamine, ethylene glycol tetraacetic acid, 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid, penicillamine, Deferasirox, Deferiprone, Deferoxamine, 2,3-disulfanylpropane-1-ol, Dexrazoxane, hexacyanoferrous acid (II,III) iron (II,III), (R)-5-(1,2-dithiolan-3-yl) pentanoic acid, 2,3-dimercapto-1-propanesulfonic acid, dimercaptosuccinic acid, or diethylenetriaminepentaacetic acid.

[0148] A buffer may be added. Non-limiting examples of buffers include phosphate, citrate, acetate, borate, TAPS, bicine, tris, tricine, TAPSO, HEPES, TES, MOPS, PIPES, cacodylate, SSC, MES, or succinic acid.

[0149] A cosolvent may be added. Non-limiting examples of cosolvents include hydroxyl groups or other polar groups, such as alcohols, such as isopropanol; glycols, such as propylene glycol, polyethylene glycol, polypropylene glycol, glycol ethers; glycerol; polyoxyethylene alcohols and polyoxyethylene fatty acid esters. Non-limiting examples of cosolvents include hydroxyl groups or other polar groups, such as alcohols, such as isopropanol; glycols, such as propylene glycol, polyethylene glycol, polypropylene glycol, glycol ethers; glycerol; polyoxyethylene alcohols and polyoxyethylene fatty acid esters.

[0150] Supplementary compounds (such as preservatives, antioxidants, antimicrobials, including bactericides and biostabilizers, such as antibacterials, antivirals and antifungals) may also be added. Thus, the pharmaceutical composition may include preservatives, antioxidants and antimicrobials.

[0151] Preservatives can be used to inhibit undesirable microbial growth or to increase the stability of the ingredients, thereby extending the shelf life. Suitable preservatives are known in the art and include, for example, EDTA, EGTA, benzalkonium chloride or benzoic acid or benzoates, such as sodium benzoate. Antioxidants include, for example, ascorbic acid, vitamin A, vitamin E, tocopherols and similar vitamins or provitamins.

[0152] In several embodiments herein, methods of cryopreserving genetically engineered bacteria for future use are described. In several embodiments herein, methods of preserving bacteria for future use by freeze drying genetically engineered bacteria are described. In several embodiments herein, methods of cryopreserving genetically engineered fungi for future use are described. In several embodiments herein, methods of protecting genetically engineered fungi for future use by freeze drying bacteria are described.

[0153] Specific non-limiting classes of antiviral agents include reverse transcriptase inhibitors; protease inhibitors; thymidine kinase inhibitors; sugar or glycoprotein synthesis inhibitors; structural protein synthesis inhibitors; nucleoside analogs; and viral maturation inhibitors. Specific non-limiting examples of antiviral agents include nevirapine, delavirdine, efavirenz, saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, zidovudine (AZT), stavudine (d4T), lamivudine (3TC), didanosine (DDI), zalcitabine (dd C), abacavir, acyclovir, penciclovir, ribavirin, valacyclovir, ganciclovir, 1-D-ribofuranosyl-1,2,4-triazole-3-carboxamide, 9->2-hydroxy-ethoxymethylguanine, adamantanamine, 5-iodo-2'-deoxyuridine, trifluorothymidine, interferon, and adenine arabinoside.

[0154] Pharmaceutical formulations and delivery systems suitable for the compositions and methods of the present invention are known in the art (see, e.g. Remington:TheScienceandPracticeofPharmacy (2003)20 th ed., Mack Publishing Co., Easton, PA; Remington'sPharmaceuticalSciences (1990) 18 thed., Mack Publishing Co., Easton, PA; TheMerckIndex (1996)12 th ed., Merck Publishing Group, Whitehouse, NJ; Pharmaceutical Principles ofSolid Dosage Forms (1993), Technonic Publishing Co., Inc., Lancaster, Pa.; Ansel ad Soklosa, PharmaceuticalCalculations (2001)11 th ed., Lippincott Williams & Wilkins, Baltimore, MD; and Poznansky et al., Drug Delivery Systems (1980), RL Juliano, ed., Oxford, NY, pp. 253-315).

[0155] In certain embodiments, compositions include molecules configured to directly or indirectly engage inducible promoters. In some embodiments, the molecules configured to engage with inducible promoters are configured to activate inducible promoters (e.g., activate gene transcription / translation). In some embodiments, the molecules configured to engage with inducible promoters are configured to inhibit the activation of inducible promoters to gene expression. In some embodiments, the molecules configured to engage with inducible promoters include compounds, alcohols, nutrients, metals, amino acids (e.g., amino acids such as synthetic amino acids), sugars or sugar analogs (e.g., lactose, arabinose, IPTG), peptides or proteins. In certain embodiments, compositions include lactose, arabinose, IPTG, tryptophan or tetracycline.

[0156] In certain embodiments herein, a method for preparing a nucleic acid for transformation or integration into a microbial genome is described. The method may include providing a nucleic acid sequence encoding a peptide, and connecting the nucleic acid sequence to a nucleic acid sequence encoding a regulatory element or a nucleic acid encoding a secretory peptide. In some embodiments, the nucleic acid comprises a sequence encoding a peptide, wherein the peptide comprises an amino acid sequence of a secretory peptide. In some embodiments, the nucleic acid comprises a signal sequence for secretion. In some embodiments, the nucleic acid comprises a sequence, or encodes a polypeptide sequence recognized by a cell secretory pathway. In some embodiments, the nucleic acid encodes a non-secreted protein (e.g., an enzyme) for producing a target biomolecule. In some embodiments, the signal sequence for secretion comprises a sequence SEQ ID NO: 212, SEQ ID NO: 213, SEQ ID NO: 214, SEQ ID NO: 215 or SEQ ID NO: 216.

[0157] It will be appreciated by those skilled in the art that gene expression levels depend on many factors, such as promoter sequences and regulatory elements. Another factor for maximum protein selection is the matching of the codons of the transcript gene with the typical codon usage of the host. As noted for most bacteria, a small subset of codons is recognized by tRNA materials and results in translation selection, and is important in the limitation of protein expression. In this regard, many synthetic genes can be designed to improve their protein expression levels. The design process of codon optimization can change rare codons into codons known for protein expression efficiency. In some embodiments, codon selection is described, wherein codon selection can be performed by using algorithms known to those skilled in the art to produce synthetic genetic transcripts optimized for high protein yields. Programs containing algorithms for codon optimization are known to those skilled in the art. Programs can include, for example, OptimumGene TM , Algorithms, etc. In addition, the codon optimized sequences of synthesis can be commercially available, for example, from Integrated DNA Technologies and other commercially available DNA sequencing service agencies. In some embodiments, peptides for secretion are described, wherein the genes for the peptides for secretion are codons optimized for expression in humans. In some embodiments, peptides for secretion are described, wherein the genes for the complete gene transcripts are codons optimized for expression bacteria, which may include secretory peptides and gene transcripts of other peptides known to improve expression levels. In some embodiments, peptides are described, wherein the genes for the secretory peptides are optimized to select codons specifically for protein expression in bacteria and fungal cells.

[0158] The term "subject" includes, but is not limited to, a subject with a disease that will benefit from contact with or administration of a genetically modified microorganism as described herein or a subject at risk of the disease. Subjects include mammals (mammals), such as humans, non-human primates (apes, gibbons, gorillas, chimpanzees, orangutans, macaques), domestic or companion animals (dogs and cats), farm animals (e.g., fowl such as chickens and ducks, horses, cattle, goats, sheep, pigs), and experimental animals (mice, rats, rabbits, guinea pigs). Subjects include veterinary animals, as well as animal disease models, for example, mice and other animal models with skin diseases.

[0159] The genetically modified microorganisms of the present invention and compositions comprising the genetically modified microorganisms can be used in various methods and uses and medicines. Such methods and uses and medicines include, for example, in vitro and in vivo administration. In various embodiments, the methods and uses and medicines provided include methods and uses and medicines for treating skin diseases.

[0160] Skin diseases can be caused by a genetic predisposition to skin conditions and by disturbances in the natural flora or natural bacteria that may reside on the skin. There are several types of skin conditions, such as, but not limited to, acne, actinic keratosis, alopecia areata, athlete's foot, onchomychosis, atopic dermatitis, underarm odor, eczema, fungal nail infections, psoriasis, rosacea, chronic wound healing, folliculitis, keratosis pilaris, perioral dermatitis, angiofibroma, skin inflammation, cosmesis, aging damage, skin discoloration, premature graying of hair, or seborrheic dermatitis. In several embodiments described herein, methods of treating skin conditions are described. In several embodiments, methods of treating rosacea are described. In several embodiments, methods of treating alopecia are described. In several embodiments, methods of onychomycosis are described. In several embodiments, methods of treating underarm odor are described. In several embodiments, methods of treating chronic wound healing are described. In several embodiments, methods of treating premature graying of hair are described. In several embodiments, methods of treating skin inflammation are described. In several embodiments, methods of treating skin discoloration are described.

[0161] Acne or acne vulgaris is a common skin disease that can affect the face, neck, chest and back. It is characterized by areas on the skin with seborrhea. The skin areas with acne may also have comedones, papules, nodules, cysts, boils, cystic acne and papules. Acne can be caused by hormones (such as testosterone) and can be affected by the associated sebaceous glands. The causes of acne may come from hormonal influences, genetic influences and infectious influences. Treatment of acne can be the use of topical medications such as benzoyl peroxide, salicylic acid and hormones. More commonly, acne can be treated with antibiotics, however, many types of antibiotics become less effective in cases where bacterial resistance can develop.

[0162] Propionibacterium acnes (P. acnes) is an anaerobic bacterial species widely inferred to cause acne. Staphylococcus aureus, a natural plant-borne skin bacterium, is also considered a conditional pathogen that infects the skin, even though it can be seen in both healthy and infected skin. However, studies have shown that P. acnes and S. aureus are already developing antibiotic resistance, thereby increasing the need to develop new therapies for skin conditions that are typically treated with antibiotics. In several embodiments described herein, genetically modified bacteria that secrete biomolecules are used to treat acne. In several embodiments described herein, genetically modified fungi that secrete biomolecules are used to treat acne.

[0163] Rosacea as used herein refers to a chronic condition characterized by facial redness and sometimes acne. There are four subtypes of rosacea, three affecting the skin and the fourth affecting the eyes (ocular rosacea). Early treatments were with topical steroids, however, treatment in the form of topical steroids can make the condition worse with long-term use. Therefore, new treatments have been investigated. Rosacea affects both sexes, but is almost three times more common in women.

[0164] Rosacea begins with redness on the cheeks, nose, or forehead of the central face, but may also less commonly affect the neck, chest, ears, and scalp. In some cases, other symptoms such as semipermanent redness, telangiectasia (dilated blood vessels in the superficial layers of the face), red domed papules (small bumps) and pustules, red, rough eyes, burning and stinging sensations, and in some advanced cases, a red, scaly nose, called a thinophyma, may form. Triggers that cause flushing and redness play a role in the development of rosacea. Exposure to extreme temperatures can cause the face to become flushed, as can strenuous exercise, heat from the sun, severe sunburn, stress, anxiety, cold drafts, and moving from a cold environment to a warm or hot environment such as heated shops and offices in the winter. There are also foods and drinks that can trigger flushing, including alcohol, foods and drinks containing caffeine (especially hot tea and coffee), foods high in histamine, and spicy foods.

[0165] Certain medications and topical irritants can quickly trigger rosacea. Some acne and wrinkle treatments that have been reported to cause rosacea include microdermabrasion and chemical peels, as well as high doses of isotretinoin, benzoyl peroxide, and tretinoin. Steroid induced rosacea is the term given to rosacea caused by the use of topical or nasal steroids. These steroids are often prescribed for seborrheic dermatitis. The dose should be slowly reduced and not stopped immediately to avoid flare-ups. The gut flora may play a role in causing the disease.

[0166] Oral tetracycline antibiotics (tetracycline, doxycycline, minocycline) and topical antibiotics (such as metronidazole) are usually the first line of defense prescribed by doctors to reduce papules, pustules, inflammation, and some redness.

[0167] Oral antibiotics can help relieve the symptoms of ocular rosacea. If papules and pustules persist, isotretinoin can sometimes be prescribed. Isotretinoin has many side effects and is usually used to treat severe acne, but has been shown to be effective for papulopustular and hyperplastic granuloma rosacea at low doses. Some individuals respond well to topical application of sandalwood oil in the infected area, particularly in reducing the prevalence of pustules and erythema. Oral antibiotics can be the first line of defense against bacteria on the skin that can trigger rosacea, but due to the rise of antibiotic resistance, new developments have been sought to treat bacterial diseases of the skin as well as rosacea. In several embodiments described herein, genetically modified microorganisms are used to treat rosacea.

[0168] Alopecia areata (AA), as used herein, refers to a condition in which hair is lost from some or all areas of the body, usually from the scalp. Because it causes bald patches on the scalp, especially in the first stages, it is sometimes called alopecia areata. In 1-2% of cases, the condition spreads to the entire scalp (alopecia totalis) or the entire epidermis (alopecia universalis). Conditions similar to AA and with similar causes also occur in other species.

[0169] The condition is considered a systemic autoimmune disease in which the body attacks its own antigenic hair follicles and inhibits or prevents hair growth. T cell lymphocytes cluster around the infected follicles, causing inflammation and subsequent hair loss. Some cases of infants born with congenital AA have been reported, but these are not cases of autoimmune disease because the infants are born without a clearly developed immune system. Defects in endogenous retinoid metabolism are a key part of the pathogenesis of AA. In addition, some evidence suggests that AA affects the part of the hair follicle associated with hair color. Graying hair is not affected. In some embodiments, genetically modified microorganisms are used to treat immune diseases.

[0170] Onychomycosis refers to fungal infection of the nail. The infection can be caused by pathogens of onychomycosis, which include dermatophytes, Candida, and non-dermatophyte molds. Dermatophytes are the fungi that most often cause onychomycosis in temperate Western countries; while Candida and non-dermatophyte molds are more often found in tropical and subtropical areas with hot and humid climates. Pathogens can include Candida and non-dermatophyte molds, particularly mold-generating Scytalidium (Neoscytalidium), Scopulariopsis, and members of the genus Aspergillus. Candida mainly causes nail onychomycosis in people whose hands are often submerged in water. Scytalidium mainly infects people in tropical areas, although it still exists if they later migrate to temperate climate areas. Treatment mainly includes topical or antifungal drugs, such as terbinafine, itraconazole, and fluconazole.

[0171] Bromhidrosis refers to body odor in which the sebaceous glands and apocrine glands play a role. The medical condition may be referred to as bromhidrosis, apocrine bromhidrosis, bromhidrosis, dermatohidrosis, bromhidrosis, and malodorous sweating. Bromhidrosis or bromhidrosis is defined by malodor due to the water-rich environment supporting bacterial growth, which is also caused by abnormally increased sweat. In some embodiments, methods of treating bromhidrosis are used.

[0172] "Poor wound healing" can be caused by a poor immune system, diabetes, low human growth hormone, rheumatoid arthritis, poor circulation from vascular or arterial disease, zinc deficiency, vitamin deficiency, lupus, etc. In several cases, poor wound healing can lead to opportunistic infections caused by normal flora. In several embodiments, therapies for wound healing using genetically modified microorganisms are described.

[0173] "Skin inflammation" and "chronic skin inflammation" can be marked by macrophage infiltration in the dermis. During infection, macrophage responses will mediate chronic inflammation, which is visible in several inflammatory skin diseases, including but not limited to psoriasis, atopic dermatitis and chronic contact dermatitis. In order to reduce the inflammatory response, therapies that seek to eliminate macrophages at the site of inflammation have been described. One way is to block the activity of effector molecules or cytokines produced by macrophages. Another way is to target macrophages during inflammation by engineered immunotoxins to eliminate them locally by apoptosis. Therapy can be other skin disorders caused by skin inflammation or chronic skin inflammation, such as skin graft-versus-host disease, lichenoids, Schlerodermatous, annular granuloma, chronic contact dermatitis, psoriasis, UV skin damage, atopic dermatitis and cutaneous T-lymphoma. However, most ways to eliminate local responses are time-consuming. In this regard, allowing genetically engineered microbial populations to locally eliminate macrophages at the site of chronic skin inflammation can provide rapid treatment for skin inflammation or chronic skin inflammation.

[0174] The present invention provides kits comprising genetically modified microorganisms (e.g., Propionibacterium bacteria) packaged in suitable packaging materials, compositions thereof, and pharmaceutical preparations. The kits can be used for various in vitro, ex vivo, and in vivo methods and uses, such as the methods or uses disclosed herein.

[0175] The kit generally includes a label or package insert including a description of the components therein or a description of the in vitro, in vivo or ex vivo use of the components therein. The kit may include a collection of such components, such as a genetically modified microorganism, such as a Propionibacterium bacterium, alone or in combination with another therapeutically useful composition (e.g., an anti-inflammatory agent).

[0176] The term "packaging material" refers to a physical structure that holds the components of a kit. The packaging material can sterilely hold the components and can be made of materials commonly used for such purposes (e.g., paper, corrugated fiber, glass, plastic, foil, ampoules, vials, tubes, etc.).

[0177] The kit of the present invention may include a label or insert. The label or insert includes a "printed matter", such as paper or cardboard, which is separated or fixed from the component, the kit or packaging material (such as a box), or attached to an ampoule, tube or bottle containing the kit components. The label or insert may additionally include a computer-readable medium, such as a disk (e.g., a hard disk), an optical disk such as a CD or DVD-ROM / RAM, a DVD, an MP3, a magnetic tape or an electrical storage medium such as a RAM and a ROM or a mixture of these, such as a magnetic / optical storage medium, a FLASH medium or a memory type card.

[0178] The label or insert may include information on the identification of one or more of the components, the dosage, the clinical pharmacology of the active ingredient, including the mechanism of action, pharmacokinetics, and pharmacodynamics. The label or insert may include information identifying the manufacturer, batch number, manufacturer's location, and date.

[0179] The label or insert may include information about the condition, disorder, disease or symptom for which the kit components may be used. The label or insert may include instructions for a clinician or subject to use one or more kit components in a method, use, treatment regimen or treatment regimen. The instructions may include the amount, frequency or duration of the dosage, as well as instructions for implementing any of the methods and uses, treatment regimens or treatment regimens described herein.

[0180] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described herein.

[0181] All applications, publications, patents, and other references, GenBank citations, and ATCC citations cited herein are incorporated by reference in their entirety. In the event of a conflict, the specification, including definitions, will control.

[0182] With respect to substantially any plural and / or singular terms used herein, those skilled in the art may convert from the plural to the singular and / or from the singular to the plural, depending on the context and / or application. Thus, unless the context clearly indicates otherwise, the singular forms "a", "an", and "the" include plural referents. For the sake of clarity, various singular / plural permutations may be expressly set forth herein. Thus, reference to "a protein" or "a gene", for example, includes a plurality of proteins or a plurality of genes.

[0183] Those skilled in the art will understand that, in general, the terms used herein, and particularly in the appended claims (e.g., the bodies of the appended claims), are generally intended to be “open” terms (e.g., the term “including” should be interpreted as “including but not limited to,” the term “having” should be interpreted as “having at least,” the term “comprising” should be interpreted as “including but not limited to,” etc.). Those skilled in the art will further understand that if a specific number of an introduced claim statement is beneficial, such an intent will be explicitly stated in the claim, and in the absence of such a statement, no such intent is present. For example, to aid understanding, the following appended claims may contain usage of the introductory phrases “at least one” and “one or more” to introduce claim statements. However, the use of such phrases should not be construed as meaning that a claim recitation introduced by the indefinite article "a" or "an" limits any particular claim containing such introduced claim recitation to a claim containing only one such recitation, even when the same claim includes the introductory phrases "one or more" or "at least one" and an indefinite article such as "a" or "an" (e.g., "a" and / or "an" should generally be construed to mean "at least one" or "one or more"); the same applies to definite articles used to introduce claim recitations. Furthermore, even if a specific number of an introduced claim recitation is explicitly recited, those skilled in the art will recognize that such a recitation should generally be construed to mean at least the recited number (e.g., the unmodified recitation "two recitations" without other modifiers means at least two recitations or two or more recitations). Furthermore, where phrases similar to "at least one of A, B, and C, etc." are used, generally such constructions mean that one skilled in the art will understand the phrase (e.g., "a system having at least one of A, B, and C" will include, but is not limited to, systems having A alone, B alone, C alone, A and B together, A and C together, B and C together, and / or A, B, and C together, etc.). In those cases where phrases similar to "at least one of A, B, or C, etc." are used, generally such constructions mean that one skilled in the art will understand the phrase (e.g., "A system having at least one of A, B, or C" will include, but is not limited to, systems having A alone, B alone, C alone, A and B together, A and C together, B and C together, and / or A, B, and C together, etc. It will be further understood by those skilled in the art that transition words and / or phrases that generally indicate two or more optional terms, whether in the specification, claims, or drawings, should be understood to contemplate the possibility of including one of the terms, any one of the terms, or both of the terms. For example, the phrase "A or B" should be understood to include the possibility of "A" or "B" or "A and B".

[0184] In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group.

[0185] As used herein, numerical values ​​are generally presented in range format throughout this document. However, the use of range format is only for convenience and brevity, and should not be interpreted as a fixed limitation on the scope of the present invention. Therefore, the use of ranges explicitly includes all possible subranges, all individual values ​​within the range, and all values ​​or ranges of values ​​include integers within such ranges and fractions of values ​​or integers within such ranges, unless the context clearly indicates otherwise. Regardless of the width of the range, this structure is applicable in all contexts in this patent document. Therefore, all ranges disclosed herein also include any and all possible subranges and combinations of subranges thereof. Any listed range can be easily considered to fully describe and enable the same range to be decomposed into at least equal halves, one-third, one-quarter, one-fifth, one-tenth, etc. For non-limiting examples, each range discussed herein can be easily decomposed into the lower third, the middle third, and the upper third, etc. It will be understood by those skilled in the art that all languages, such as "up to", "at least", "greater than", "less than", etc., include the numbers listed, and refer to the ranges that can be subsequently decomposed into subranges as described above. Finally, as will be understood by those skilled in the art, ranges include each individual member. Thus, for example, a group having 1-3 items refers to groups having 1, 2, or 3 items. Similarly, a group having 1-5 items refers to groups having 1, 2, 3, 4, or 5 items, and so on.

[0186] Although various aspects and embodiments have been disclosed herein, other aspects and embodiments will be apparent to those skilled in the art. The various aspects and embodiments disclosed herein are for purposes of illustration and are not intended to be limiting, with the true scope and spirit being indicated by the appended claims.

[0187] Those skilled in the art will appreciate that for this and other processes and methods disclosed herein, the functions performed in the processes and methods may be implemented in different orders. In addition, the steps and operations outlined are provided only as examples, and some steps and operations may be optional, combined into fewer steps and operations, or expanded into additional steps and operations without departing from the essence of the disclosed embodiments.

[0188] Those skilled in the art will appreciate that for this and other processes and methods disclosed herein, the functions performed in the processes and methods may be implemented in different orders. In addition, the steps and operations outlined are provided only as examples, and some steps and operations may be optional, combined into fewer steps and operations, or expanded into additional steps and operations without departing from the essence of the disclosed embodiments.

[0189] The examples set forth below illustrate certain implementations and do not limit the present technology. Example Example 1: Isolation of RT6 P. acnes strain

[0190] Bacteria were collected from human skin using E-swab (Fisher) as follows: volunteer subjects were asked to wash their faces with soap and water and clean their faces with ethanol wipes before applying E-swab on their cheeks and foreheads. The applicator was next transferred to a tube with transfer medium. The tube was vortexed to release the bacteria into the medium. A 100-fold dilution of the transfer medium was spread on RIC plates. After one week of anaerobic growth, colonies were observed on each plate. These colonies were grown in BHI medium until they reached a suitable density for DNA isolation. Genomic DNA was prepared using a commercial kit (Epicentre) and PCR amplified using P. acnes specific 16S rDNA primers Pas9 / Pas11 (Table 1). The PCR fragment was gel purified and sequenced using primer 16SFseq. The sequence was compared with the 16S rDNA gene (NC_017550, SEQ ID NO:290). Colonies showing a C to T transition at nucleotide 1315 were classified as type II RT6. Colonies with the RecA gene were also tested to confirm that they belonged to type II strains. After PCR amplification with primers RecAF / RecAR, the fragments were gel purified and sequenced with primers RecAFseq and RecARseq. The combination of sequences obtained with the two primers covered more than 90% of the RecA gene. The sequenced RecA fragments were aligned to the reference sequence of the RecA genes from ATCC11828 and ATCC6919 strains. Table 1. Primers used to isolate RT6 P. acnes strains Example 2. Molecular cloning

[0191] PCR amplification was performed using Q5 high-fidelity DNA polymerase (New England Biolab) and a PCR machine (Eppendorf) according to the manufacturer's recommendations. For gene assembly reactions, the Gibson assembly method (NEBuilder HiFi DNA Assembly Cloning Kit, New England Biolab) and the Golden Gate assembly method (NEB Golden Gate Assembly Kit, New England Biolab) were used according to the manufacturer's recommendations. Example 3. Isolation of genomic DNA.

[0192] Total genomic DNA was isolated from bacterial strains by phenol-chloroform extraction with minor changes to the procedure described by Rhee (2011). P. acnes strains were grown in brain heart infusion broth (BHI) at 37°C until late logarithmic phase. After harvesting the cells, the cell pellets were resuspended with 10 mM Tris-Cl pH 8.0, 10 mM Na 2EDTA, and lysozyme (final concentration = 1 mg / mL) was added. After incubation at 37°C for 20 min, 10% SDS (final concentration = 1.4%) was added and incubated on ice for 10 min. The lysate was extracted three times with an equal volume of a phenol-chloroform mixture (phenol, chloroform, and isoamyl alcohol in a ratio of 25:24:1), and the DNA was then precipitated with ethanol and dried. Example 4. Electroporation of P. acnes.

[0193] P. acnes was transformed according to the methods described by Cheong (2008) and Rhee et al. (2007). Cells were grown in 9 mL of BHI containing Oxyrase for broth in 13×100 screw-cap tubes until OD600nm reached approximately 0.5. Cells were collected by centrifugation (4°C; 4300 g; 10 minutes) and washed three times with ice-cold SG medium (glycerol, 10%; sucrose, 0.5 M). Cells were resuspended in SG medium (approximately 5×109 -1010 CFU / ml). These electrocompetent cells were used immediately. 75 microliters of cell suspension were mixed with DNA and transferred to a frozen electroporation cup (1 mm gap). The electroporation conditions using the Bio-Rad electroporator were 1.5 KV, 25 μF and 600 Ω. The time constant was set between 8.5 ms and 10 ms. After electroporation, cells were transferred to 2 ml of preheated (37°C) BHI containing Oxyrase for liquid culture medium. The cells were incubated at 37°C for 10 hours. Cells were collected by centrifugation (2000 × g, 10 minutes) at room temperature and plated on reinforced Clostridium agar plates with antibiotics. The plates were incubated at 37°C under anaerobic conditions. Example 5. Construction of a growth-inhibiting strain of Bacillus subtilis

[0194] The genomic DNA of Bacillus subtilis strain 168 was used as a template, and the truncated dnaA gene of Bacillus subtilis was amplified by PCR using primers (d-B_F: aggaaggaTCCATGGAAAATATATTAGACCTG (SEQ ID NO: 224), d-B_R: ctatgaccatgattacgCGCATGAATAACGGTCGTATG (SEQ ID NO: 225)). The DNA region with the chloramphenicol gene and IPTG inducible promoter was amplified by PCR using primers (125_F: gcctgcaggtcgactTTAAGTTATTGGTATGACTGGTTTTAAG (SEQ ID NO: 226), 125_R: tccatggaTCCTTCCTCCTTTAATTGG (SEQ ID NO: 227)). These PCR products were obtained by HiFi DNA Assembly Cloning Kit was assembled. The product was digested with HindIII and the 3,257 bp fragment was self-ligated. The self-ligated DNA was transformed into Bacillus subtilis strains and transformants were selected on LB with Cm (5 μg / mL) and IPTG at different concentrations (0, 0.05, 0.1 and 0.25 mM). Example 6. Construction of a growth inhibitory strain of P. acnes.

[0195] Arabinose-inducible fts operon. Genomic DNA of Bacillus subtilis strain 168 was used as template and primers (araRE F: The arabinose-inducible promoter and regulator of Bacillus subtilis were amplified by PCR (TGCAGTTCTAGACGACACAGGCTGACGAAATTA (SEQ ID NO: 228), araRE R: CGTAGCGAATTCCATTTCCCTGCCCTCCCGAA (SEQ ID NO: 229)). The 1468 bp PCR product was ligated into pUC18 digested with XbaI and EcoRI. The truncated fts operon of P. acnes was amplified by PCR using genomic DNA of P. acnes strain ATCC11828 as template and primers (ftzope F: CTGACTGAATTCGCTTCCCAACGGGGCCGTTT (SEQ ID NO: 230), ftzope R: GACTGCGAATTCCTGAAGAGCCGTCACCGACA (SEQ ID NO: 231)). The 1332 bp PCR product digested by EcoRI was ligated into pUC18 with arabinose promoter also digested by EcoRI. After inserting 1236 bp DNA with erythromycin gene, the plasmid was introduced into P. acnes strain, and transformants were selected on modified enhanced Clostridial medium with L-arabinose (1.5% w / v). Example 7. Lactose-inducible dnaA gene. The genomic DNA of Propionibacterium acnes strain ATCC11828 was used as a template by PCR with primers (0410-1F: GGCTTCTGGTCTCGAGTGTTGTGGAACGACAACA (SEQ ID NO: 232), 0410-1R: The β-galactose promoter region and the truncated dnaA gene of Propionibacterium acnes were amplified by 0410-2F: GGCTTCTGGTCTCGCCATGTCCGACACACCGTTC (SEQ ID NO: 234), 0410-2R: GGCTTCTGGTCTCGGGTAGAGACTGGGTAGAGACG (SEQ ID NO: 235). These PCR products and DNA fragments with antibiotic genes, erythromycin and chloramphenicol genes were ligated into pUC18 by Golden Gate assembly (NEB Golden Gate Assembly Kit, New England Biolab). The plasmid was introduced into the Propionibacterium acnes strain and transformants were selected on modified enhanced clostridial medium with lactose (1.0% w / v). Table 2. Primer list Example 8. Construction of CAMPII mutant Propionibacterium acnes strain.

[0196] From the start codon of the CAMPII gene of Propionibacterium acnes, genomic DNA of Propionibacterium acnes ATCC11828 strain was used as a template by PCR, and primers (0422NB-1F: AGTAAACTTGGTCTGACATGAAGAAGACCCATCTTG (SEQ ID NO: 242), 0422NB-1R: TATATATATTTATTATCCGATGGACCTTGTTTTGGAGAG (SEQ ID NO: 243)) were used to amplify a 400 bp truncated ORF. The 438 bp PCR product and the DNA fragment with erythromycin and chloramphenicol resistance genes were connected to pUC18 by NEBuilder HiFi DNA Assembly Cloning Kit, and the transformant of the connection product was selected on LB plates with amp (100 μg / mL) and cm (20 mg / mL). After transformation into E. coli dcm-dam- strain, the plasmid was introduced into P. acnes and selected anaerobically on enhanced clostridial medium plates with erm (5 μg / mL) or cm (5 μg / mL). CAMPII mutant colonies were checked by PCR. Example 9. Construction of marker-free mutant Propionibacterium acnes strains ( Fig. 9 ).

[0197] The upstream and downstream regions of the target gene are amplified by PCR. These regions should be greater than 500bp. These DNA fragments are connected to a plasmid with an antibiotic marker and without the replication origin of Propionibacterium acnes. The suicide vector is introduced into Propionibacterium acnes, and transformants are selected by antibiotics. After confirming these, the cells are cultured in an enhanced Clostridium medium without antibiotics to allow a second homologous recombination. After streaking on a plate, unmarked mutant colonies are screened by PCR. Example 10. Construction of lactose-inducible IL10-secreting Propionibacterium acnes strain.

[0198] PCR was performed using genomic DNA of Propionibacterium acnes strain ATCC11828 as a template and primers (0505-1F: The 1037 bp β-galactose promoter region of P. acnes was amplified by PCR using genomic DNA of Bacillus subtilis strain 168 as a template and primers (0505-2_F: GGTTGGTGCCATGTTTGCAAAACGATTCAAAAC (SEQ ID NO: 246), 0505-2_R: AGGAGTGCATATGATAAATAGACATGGTTCCG (SEQ ID NO: 247)) to amplify the 188 bp signal peptide region. 568 bp of human IL10 ORF was amplified by PCR (0505-3_F: CTATTTATCATATGCACTCCTCCGCTCTG (SEQ ID NO: 248), 0505-3_R: TTATCCGATTCATGAGACTGTCAGTTGCGGATCTTCATGG (SEQ ID NO: 249)). These PCR products and DNA fragments with erythromycin and chloramphenicol resistance genes were ligated to pUC18 by NEBuilder HiFi DNA assembly cloning kit, and transformants of the ligated products were selected on LB plates with amp (100 μg / mL) and cm (20 mg / mL). After transformation into E. coli dcm-dam- strain, the plasmid was introduced into Propionibacterium acnes and anaerobically selected on enhanced Clostridium media plates with erm (5 μg / mL) or cm (5 μg / mL). After checking the transformants by PCR, the induction of lactose and the secretion of IL10 were analyzed by ELISA. Example 11. MC / 9 cell culture.

[0199] Murine MC / 9 cells were obtained from ATCC (CRL-8306) and propagated in DMEM supplemented with 10% FBS (Gibco), 10% rat T-STIM (BD), 2 mM glutamate, 0.05 mM 2-mercaptoethanol, and penicillin / streptomycin (pen / strep). Cells were cultured at 2 × 10 5 The density of cells / ml was maintained. Example 12. Functional assay of IL-10.

[0200] The recombinant human IL-10 purified was quantified using the commercial ELISA (Biolegend) for human IL-10. The biological activity of the IL-10 expressed was tested by the dose-dependent costimulation (using human IL-4) of MC / 9 cell proliferation. In brief, the cells were centrifuged and washed twice with RPMI1640 (Gibco) to remove all traces of Rat-T-STIM in the growth medium. Next, the cells were resuspended in DMEM supplemented with 10% FBS, 2mM glutamic acid, penicillin / streptomycin, 2-mercaptoethanol and 200pg / ml human IL-4 (Peprotech), and plated in 96-well plates at a density of 20,000 cells / well. Standard curves were generated using commercial recombinant human IL-10 (Peprotech). Cells were grown for 82 hours, and cell proliferation was determined using XTT assay (Biotium). Example 13. Isolation of R6 Type II P. acnes.

[0201] Isolated P. acnes strains were examined to determine what ribotype they were, with the goal of isolating type II RT6 P. acnes. From the alignment of the RecA genes from type II and type I strains ( Fig.10 ), we can see 10 nucleotide differences. These variations are used to identify the subtypes of P. acnes. ATCC strain 11828 was used as a positive control for type II P. acnes.

[0202] The RecA gene sequenced from the putative RT6 clone was aligned with region 720-1191 of the RecA gene from strain ATTCC11828 ( Fig.11 ). Alignment with the type I strain NCTC 737 showed a 5 bp variation, indicating that the colony was a type II strain.

[0203] In addition, the RecA gene sequenced from the putative RT6 clone was identical to that from The region 64-325 of the RecA gene of strain ATTCC11828 (SEQ ID NO: 276) was aligned. Alignment with type I strain NCTC 737 (SEQ ID NO: 277) showed a 3 bp variation, indicating that the colony was a type II strain.

[0204] The SNP sequence of ATCC11828 was compared with the RT6 SNP sequence from the literature and 9 isolates (C→T at 1315) ( Fig.12 ). Nine isolates from our study matched the published RT6 SNP sequence (eg, Fitz-Gibbon, S., et al., (2013) Invest. Dermatol., 133(9):2152-60). Example 14. Knock-in of human IL-10, EGF and HGH genes into RT6 Propionibacterium acnes strain.

[0205] The genes for human IL-10, human EGF, and human GH were all cloned into separate P. acnes strains under the inducible LacZ promoter. When the cells were incubated with 0.1 mM IPTG, we began to see expression and secretion of the corresponding genes in the growth medium ( Fig.13 ). Example 15. Growth arrest of Propionibacterium acnes by introduction of an inducible promoter into a housekeeping gene.

[0206] Growth of P. acnes was only achieved when induced by IPTG (Table 3). The same construct was prepared with an arabinose inducible promoter, allowing control of human gene secretion and growth arrest by nutrients alone. Table 3. Example 16. Construction of CAMPII mutants and IL-10 expressing strains of Propionibacterium acnes.

[0207] The 1100bp region (primers Up-CF and Up-CR) and 400bp truncated CAMPIIORF (primers CAMPII F and CAMPII R) of the upstream of CAMPIIORF of Propionibacterium acnes were amplified by PCR with the genomic DNA of acne ATCC 11828 strain. For the secretion of IL10, the genomic DNA of Bacillus subtilis strain 168 was used as a template (primers Sig-CF and Sig-CR) to produce a 168bp signal peptide region. 568bp of people's IL10 ORF was amplified by PCR (primers I10-CF and I10-CR). These PCR products and the DNA fragment with erythromycin resistance gene were connected to pUC19 by NEBuilder HiFi DNA assembly cloning kit, and the transformant of the connection product was selected on the LB plate with amp (100 μg / mL). After transformation into E. coli dcm-dam-strain, the plasmid was introduced into P. acnes and selected anaerobically on enhanced Clostridium medium (RCM) plates with erm (5 μg / mL). Transformants with the IL-10 gene of the CAMPII promoter and signal peptide were checked by PCR. For the construction of CAMPII mutant strains, the transformants were cultured in RCM without erythromycin to allow a second homologous recombination. After streaking on the plates, CAMPII mutant colonies were screened by PCR. Table 4. Primer list Example 17. Construction of GAPDH mutant and IL-10 expressing strain of Propionibacterium acnes.

[0208] The 1000 bp upstream region of the GAPDH ORF of P. acnes (primers Up-GF and Up-GR) and the 400 bp truncated GAPDH ORF (primers Gapdh F and gapdh R) were amplified by PCR using genomic DNA of acnes ATCC 11828 strain. For the secretion of IL10, the genomic DNA of Bacillus subtilis strain 168 was used as a template (primers Sig-GF and Sig-GR) to generate a 168 bp signal peptide region by PCR. The 568 bp human IL10 ORF was amplified by PCR (primers I10-GF and I10-GR). These PCR products and the DNA fragment with erythromycin resistance gene were connected to pUC19 by NEBuilder HiFi DNA assembly cloning kit, and the transformants of the connected products were selected on LB plates with amp (100 μg / mL). After transformation into E. coli dcm-dam-strain, the plasmid was introduced into P. acnes and selected anaerobically on enhanced Clostridium medium (RCM) plates with erm (5 μg / mL). Transformants with the IL-10 gene with the GAPDH promoter and signal peptide were checked by PCR. In order to construct a GAPDH mutant strain, the transformant was cultured in a modified RCM (m-RCM) containing lactate and without erythromycin to allow a second homologous recombination. After streaking on m-RCM and RCM plates containing lactate, colonies that grew only on m-RCM containing lactate were selected and these mutants were checked by PCR. Table 5. Primer list Example 18. References M, MT (2010). Mutagenesis of Propionibacterium acnes and analysis of two CAMP factor knock-out mutants. J Microbiol Methods, 211-216. Rhee MS, Moritz BE, Xie G, Glavina Del Rio T, Dalin E, Tice H, Bruce D, Goodwin L, Chertkov O, Brettin T, Han C, Detter C, Pitluck S, Land ML, Patel M, Ou M, Harbrucker R, Ingram LO, Shanmugam KT. (2011). Complete Genome Sequence of a thermotolerant sporogenic lactic acid bacterium, Bacillus coagulans strain. Standards in Genomic Sciences 5, 331 - 340. Rhee MS, Kim JW, Qian YL, Ingram LO, Shanmugam KT. (2007). Development of plasmid vector and electroporation condition for gene transfer in sporogenic lactic acid bacterium, Bacillus coagulans. Plasmid 58:13 - 22. Cheong D , Lee H.I. , So JS . (2008). Optimization of electrotransformation conditions for Propionibacterium acnes. J Microbiol Methods. 72(1):38 - 41. Rhee MS, Wei L, Sawhney N, Rice JD., St.John F, Hurlbert, JC, Preston, JF. (2014). Engineering the xylan utilization system in Bacillus subtilis for production of acidic xylooligosaccharides. Appl.Environ.Microbiol. 80(3)917 - 927. Example 19. Representative non - limiting embodiments.

[0209] A1. A method for preparing a nucleic acid for controlled expression of a peptide for treatment, comprising providing a first nucleic acid sequence encoding an operon sequence for controlled expression; linking the first nucleic acid sequence to a second nucleic acid sequence encoding a first peptide; and Nucleic acids for controlled expression of therapeutic peptides are optimized for protein expression.

[0210] A2. A method according to embodiment A1, wherein the operon is a prokaryotic operon.

[0211] A3. A method according to embodiment A2, wherein the operator is a lac operator.

[0212] A4. A method according to embodiment A2, wherein the operator is the Trp operator.

[0213] A5. A method according to embodiment A1, wherein the operon is a eukaryotic operon.

[0214] A6. The method of any one of embodiments A1-A5, wherein the first peptide comprises a hyaluronan synthase or a portion thereof.

[0215] A7. A method according to embodiment A6, wherein the hyaluronan synthase or a portion thereof comprises the sequence SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4.

[0216] A8. The method of any one of embodiments A1-A5, wherein the first peptide comprises elastin or a portion thereof.

[0217] A9. A method according to embodiment A8, wherein the elastin or a portion thereof comprises the sequence SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, or SEQ ID NO:17.

[0218] A10. The method of any one of embodiments A1-A5, wherein the first peptide comprises collagen or a portion thereof.

[0219] A11. A method according to embodiment A10, wherein the collagen or a portion thereof comprises the sequence SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, or SEQ ID NO:23.

[0220] A12. The method of any one of embodiments A1-A5, wherein the first peptide comprises an anti-inflammatory agent or a portion thereof.

[0221] A13. The method of embodiment A12, wherein the anti-inflammatory agent is an interleukin or a portion thereof.

[0222] A14. A method according to embodiment A12 or A13, wherein the anti-inflammatory agent or a portion thereof comprises the sequence SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, or SEQ ID NO:28.

[0223] A15. The method of any one of embodiments A1-A5, wherein the first peptide comprises a coagulation factor or a portion thereof.

[0224] A16. A method according to embodiment A15, wherein the coagulation factor or a portion thereof comprises the sequence SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, or SEQ ID NO:39.

[0225] A17. The method of any one of embodiments A1-A5, wherein the first peptide comprises an enzyme for melanin synthesis or a portion thereof.

[0226] A18. A method according to embodiment A17, wherein the enzyme for melanin synthesis or a portion thereof comprises the sequence SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, or SEQ ID NO:44.

[0227] A19. The method of any one of embodiments A1-A5, wherein the first peptide comprises a hormone or a portion thereof.

[0228] A20. A method according to embodiment A19, wherein the hormone or a portion thereof comprises the sequence SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, or SEQ ID NO:49.

[0229] A21. A method according to any one of embodiments A1-A5, wherein the first peptide comprises platelet basic protein or a portion thereof.

[0230] A22. A method according to embodiment A21, wherein the platelet basic protein or a portion thereof comprises the sequence SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, or SEQ ID NO:62.

[0231] A23. A method according to any one of embodiments A1-A5, wherein the first peptide comprises transforming growth factor or a portion thereof.

[0232] A24. A method according to embodiment A23, wherein the transforming growth factor or a portion thereof comprises the sequence SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, or SEQ ID NO:69.

[0233] A25. A method according to any one of embodiments A1-A5, wherein the first peptide comprises hepatocyte growth factor or a portion thereof.

[0234] A26. A method according to embodiment A25, wherein the hepatocyte growth factor or a portion thereof comprises the sequence SEQ ID NO:70.

[0235] A27. A method according to any one of embodiments A1-A5, wherein the first peptide comprises vascular endothelial growth factor or a portion thereof.

[0236] A28. A method according to embodiment A27, wherein the vascular endothelial growth factor or a portion thereof comprises the sequence SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, or SEQ ID NO:91.

[0237] A29. A method according to any one of embodiments A1-A5, wherein the first peptide comprises placental growth factor or a portion thereof.

[0238] A30. A method according to embodiment A29, wherein the placenta growth factor or a portion thereof comprises the sequence SEQ ID NO:92.

[0239] A31. A method according to any one of embodiments A1-A5, wherein the first peptide comprises platelet-derived growth factor or a portion thereof.

[0240] A32. A method according to embodiment A31, wherein the platelet-derived growth factor or a portion thereof comprises the sequence SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, or SEQ ID NO:102.

[0241] A33. A method according to any one of embodiments A1-A5, wherein the first peptide comprises epidermal growth factor or a portion thereof.

[0242] A34. A method according to embodiment A33, wherein the epidermal growth factor or a portion thereof comprises the sequence SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105 or SEQ ID NO:106.

[0243] A35. A method according to any one of embodiments A1-A5, wherein the first peptide comprises a fibroblast growth factor or a portion thereof.

[0244] A36. A method according to embodiment A35, wherein the fibroblast growth factor or a portion thereof comprises the sequence of SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, or SEQ ID NO:144.

[0245] A37. A method according to any one of embodiments A1-A5, wherein the first peptide comprises a DNA repair enzyme or a portion thereof.

[0246] A38. A method according to embodiment A37, wherein the DNA repair enzyme or a portion thereof is derived from a base excision repair enzyme.

[0247] A39. A method according to any one of embodiments A37 or A38, wherein the DNA repair enzyme or a portion thereof comprises the amino acid sequence of SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, or SEQ ID NO:155.

[0248] A40. A method according to embodiment A37, wherein the DNA repair enzyme or a portion thereof is derived from an enzyme for directly reversing damage.

[0249] A41. A method according to embodiment A37 or A40, wherein the enzyme for directly reversing the damage comprises the amino acid sequence SEQ ID NO:156, SEQ ID NO:157 or SEQ ID NO:158.

[0250] A42. A method according to embodiment A37, wherein the DNA repair enzyme or a portion thereof is derived from a mismatch excision repair enzyme.

[0251] A43. A method according to embodiment A37 or A42, wherein the mismatch excision repair enzyme comprises the amino acid sequence SEQ ID NO:159, SEQ ID NO:160 SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167 or SEQ ID NO:168.

[0252] A44. A method according to embodiment A37, wherein the DNA repair enzyme or a portion thereof is derived from a nucleotide excision repair enzyme.

[0253] A45. A method according to embodiment A37 or A44, wherein the nucleotide excision repair enzyme comprises the amino acid sequence of SEQ ID NO: 169, SEQ ID NO: 170 SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178, SEQ ID NO: 179, SEQ ID NO: 180 SEQ ID NO: 181, SEQ ID NO: 182, SEQ ID NO: 183, SEQ ID NO: 184, SEQ ID NO: 185, SEQ ID NO: 186, SEQ ID NO: 187, SEQ ID NO: 188, SEQ ID NO: 189, SEQ ID NO: 190 SEQ ID NO: 191, SEQ ID NO: 192, SEQ ID NO: 193, SEQ ID NO: 194, SEQ ID NO: 195, SEQ ID NO: 196, or SEQ ID NO: ID NO:197.

[0254] A46. A method according to embodiment A37, wherein the DNA repair enzyme or a portion thereof is derived from an editing or processing nuclease.

[0255] A47. A method according to embodiment A37 or A46, wherein the editing or processing nuclease comprises the amino acid sequence SEQ ID NO: 198, SEQ ID NO: 199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204 or SEQ ID NO:205.

[0256] A48. A method according to any one of embodiments A1-A5, wherein the first peptide comprises telomerase or a portion thereof.

[0257] A49. A method according to embodiment A48, wherein the telomerase or a portion thereof comprises the amino acid sequence of SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208 or SEQ ID NO:209.

[0258] A50. A method according to any one of embodiments A1-A5, wherein the first peptide comprises a protector of telomerase protein 1 or a portion thereof.

[0259] A51. A method according to embodiment A50, wherein the protector of telomerase protein 1 or a portion thereof comprises the amino acid sequence SEQ ID NO:210 or SEQ ID NO:211.

[0260] A52. A method according to any one of embodiments A1-A5, A8-A16 or A19-A51, which also includes providing a third nucleic acid sequence encoding a second peptide and connecting the third nucleic acid sequence to the second nucleic acid sequence encoding the first peptide at one end, wherein the third nucleic acid sequence is located between the first nucleic acid sequence encoding the operon sequence and the second nucleic acid sequence encoding the first peptide.

[0261] A53. The method described in any one of embodiments A1-A5, A8-A16 or A19-A51 further includes providing a third nucleic acid sequence encoding a second peptide, and connecting the third nucleic acid sequence at one end to the end of the second nucleic acid sequence encoding the first peptide, wherein the third nucleic acid sequence is located at the end of the second nucleic acid sequence opposite to the first nucleic acid sequence encoding the operon sequence.

[0262] The method according to embodiment A52 or A53, wherein the second peptide comprises SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72,SEQ ID NO:73,SEQ ID NO:74,SEQ ID NO:75,SEQ ID NO:76,SEQID NO:77SEQ ID NO:78,SEQ ID NO:79,SEQ ID NO:80,SEQ ID NO:81,SEQ ID NO:82,SEQID NO:83,SEQ ID NO:84,SEQ ID NO:85,SEQ ID NO:86,SEQ ID NO:87SEQ ID NO:88,SEQID NO:89,SEQ ID NO:90, SEQ ID NO:91,SEQ ID NO:92,SEQ ID NO:93,SEQ ID NO:94,SEQ ID NO:95,SEQID NO:96,SEQ ID NO:97SEQ ID NO:98,SEQ ID NO:99,SEQ ID NO:100,SEQ ID NO:101,SEQ ID NO:102,SEQ ID NO:103,SEQ ID NO:104,SEQ ID NO:105,SEQ ID NO:106,SEQ IDNO:107SEQ ID NO:108,SEQ ID NO:109,SEQ ID NO:110,SEQ ID NO:111,SEQ ID NO:112,SEQ ID NO:113,SEQ ID NO:114,SEQ ID NO:115,SEQ ID NO:116,SEQ ID NO:117SEQ IDNO:118,SEQ ID NO:119,SEQ ID NO:120,SEQ ID NO:121,SEQ ID NO:122,SEQ ID NO:123,SEQ ID NO:124,SEQ ID NO:125,SEQ ID NO:126,SEQ ID NO:127SEQ ID NO:128,SEQ IDNO:129,SEQ ID NO:130,SEQ ID NO:131,SEQ ID NO:132,SEQ ID NO:133,SEQ ID NO:134,SEQ ID NO:135,SEQ ID NO:136,SEQ ID NO:137SEQ ID NO:138,SEQ ID NO:139,SEQ IDNO:140,SEQ ID NO:141,SEQ ID NO:142,SEQ ID NO:143,SEQ ID NO:144,SEQ ID NO:145,SEQ ID NO:146,SEQ ID NO:147SEQ ID NO:148,SEQ ID NO:149,SEQ ID NO:150,SEQ IDNO:151,SEQ ID NO:152,SEQ ID NO:153,SEQ ID NO:154,SEQ ID NO:155,SEQ ID NO:156,SEQ ID NO:157SEQ ID NO:158,SEQ ID NO:159,SEQ ID NO:160,SEQ ID NO:161,SEQ IDNO:162,SEQ ID NO:163,SEQ ID NO:164,SEQ ID NO:165,SEQ ID NO:166,SEQ ID NO:167SEQ ID NO:168,SEQ ID NO:169,SEQ ID NO:170,SEQ ID NO:171,SEQ ID NO:172,SEQID NO:173,SEQ ID NO:174,SEQ ID NO:175,SEQ ID NO:176,SEQ ID NO:177SEQ ID NO:178,SEQ ID NO:179,SEQ ID NO:180,SEQ ID NO:181,SEQ ID NO:182,SEQ ID NO:183,SEQID NO:184,SEQ ID NO:185,SEQ ID NO:106,SEQ ID NO:187SEQ ID NO:188,SEQ ID NO:189,SEQ ID NO:190,SEQ ID NO:191,SEQ ID NO:192,SEQ ID NO:193,SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197 SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207 SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, or SEQ ID NO:211, and wherein the second peptide does not comprise the amino acid sequence of the first peptide.

[0263] A55. The method described in any one of embodiments A1-A5, A8-A16 or A19-A51 further comprises providing a nucleic acid sequence encoding a secretory peptide, and connecting the nucleic acid sequence encoding the secretory peptide at one end to the nucleic acid sequence encoding the operon, wherein the nucleic acid encoding the secretory peptide is located between the operator sequence and the second nucleic acid sequence encoding the first peptide.

[0264] A56. A method according to any one of embodiments A1-A5, A8-A16 or A19-A51, which also includes providing a nucleic acid sequence encoding a secretory peptide and connecting the nucleic acid sequence to the nucleic acid sequence encoding the second nucleic acid sequence encoding the first peptide at one end, wherein the nucleic acid sequence encoding the secretory peptide is located at the opposite end of the nucleic acid sequence encoding the operon.

[0265] A57. A method according to any one of embodiments A52-A54, which also includes providing a nucleic acid sequence encoding a secretory peptide and connecting the nucleic acid sequence encoding the secretory peptide at one end to the nucleic acid sequence encoding the operon, wherein the nucleic acid encoding the secretory peptide is located between the operator sequence and the second nucleic acid sequence encoding the first peptide or the third nucleic acid sequence encoding the second peptide.

[0266] A58. A method according to any one of embodiments A52-A54, which also includes providing a nucleic acid sequence encoding a secretory peptide, and connecting the nucleic acid sequence encoding the secretory peptide to a nucleic acid sequence encoding the second nucleic acid sequence encoding the first peptide at one end, or connecting the nucleic acid sequence encoding the secretory peptide to a nucleic acid sequence encoding the third nucleic acid sequence encoding the second peptide, wherein the nucleic acid sequence encoding the secretory peptide is located at the opposite end of the operator sequence.

[0267] A59. A method according to any one of embodiments A55-A58, wherein the secreted peptide comprises the sequence SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215 or SEQ ID NO:216.

[0268] A60. The method of any one of embodiments A1-A59, wherein the optimization is performed by computational methods.

[0269] A61. A nucleic acid for controlled expression of a peptide for use in therapy, comprising a first nucleic acid sequence encoding an operator sequence for controlled expression; a second nucleic acid sequence encoding a first peptide; and wherein the nucleic acid for controlled expression of the peptide for use in therapy is optimized for protein expression.

[0270] A62. The nucleic acid according to embodiment A61, wherein the operon is a prokaryotic operon.

[0271] A63. A nucleic acid according to embodiment A61 or A62, wherein the operon is a lac operon.

[0272] A64. A nucleic acid according to embodiment A61 or A62, wherein the operon is a Trp operon.

[0273] A65. A nucleic acid according to embodiment A61, wherein the operon is a eukaryotic operon.

[0274] A66. A nucleic acid according to any one of embodiments A61-A65, wherein the first peptide comprises a hyaluronan synthase or a portion thereof.

[0275] A67. A nucleic acid according to embodiment A66, wherein the first peptide comprises the sequence SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4.

[0276] A68. A nucleic acid according to any one of embodiments A61-A65, wherein the first peptide comprises elastin or a portion thereof.

[0277] A69. A nucleic acid according to embodiment A68, wherein the first peptide comprises the sequence SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, or SEQ ID NO:17.

[0278] A70. A nucleic acid according to any one of embodiments A61-A65, wherein the first peptide comprises collagen or a portion thereof.

[0279] A71. A nucleic acid according to embodiment A70, wherein the first peptide comprises the sequence SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, or SEQ ID NO:23.

[0280] A72. A nucleic acid according to any one of embodiments A61-A65, wherein the first peptide comprises an anti-inflammatory agent or a portion thereof.

[0281] A73. A nucleic acid according to embodiment A72, wherein the anti-inflammatory agent is an interleukin or a portion thereof.

[0282] A74. A nucleic acid according to any one of embodiments A72 or A73, wherein the first peptide comprises the sequence SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27 or SEQ ID NO:28.

[0283] A75. A nucleic acid according to any one of embodiments A61-A65, wherein the first peptide comprises a coagulation factor or a portion thereof.

[0284] A76. The nucleic acid of embodiment A75, wherein the first peptide comprises the sequence SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, or SEQ ID NO:39.

[0285] A77. A nucleic acid according to any one of embodiments A61-A65, wherein the first peptide comprises an enzyme or a portion thereof for melanin synthesis.

[0286] A78. A nucleic acid according to embodiment A77, wherein the first peptide comprises the sequence SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43 or SEQ ID NO:44.

[0287] A79. A nucleic acid according to any one of embodiments A61-A65, wherein the first peptide comprises a hormone or a portion thereof.

[0288] A80. The nucleic acid of embodiment A79, wherein the first peptide for use in treatment comprises the sequence of SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, or SEQ ID NO:49.

[0289] A81. A nucleic acid according to any one of embodiments A61-A65, wherein the first peptide comprises platelet basic protein or a portion thereof.

[0290] A82. A nucleic acid according to embodiment A81, wherein the first peptide comprises the sequence SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, or SEQ ID NO:62.

[0291] A83. A nucleic acid according to any one of embodiments A61-A65, wherein the first peptide comprises transforming growth factor or a portion thereof.

[0292] A84. A nucleic acid according to embodiment A83, wherein the first peptide comprises the sequence SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, or SEQ ID NO:69.

[0293] A85. A nucleic acid according to any one of embodiments A61-A65, wherein the first peptide comprises hepatocyte growth factor or a portion thereof.

[0294] A86. A nucleic acid according to embodiment A85, wherein the first peptide comprises the sequence SEQ ID NO:70.

[0295] A87. A nucleic acid according to any one of embodiments A61-A65, wherein the first peptide comprises vascular endothelial growth factor or a portion thereof.

[0296] A88. A nucleic acid according to embodiment A87, wherein the first peptide comprises the sequence SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQID NO:90, or SEQ ID NO:91.

[0297] A89. A nucleic acid according to any one of embodiments A61-A65, wherein the first peptide comprises placental growth factor or a portion thereof.

[0298] A90. A nucleic acid according to embodiment A89, wherein the first peptide comprises the sequence SEQ ID NO:92.

[0299] A91. A nucleic acid according to any one of embodiments A61-A65, wherein the first peptide comprises platelet-derived growth factor or a portion thereof.

[0300] A92. A nucleic acid according to embodiment A91, wherein the first peptide comprises the sequence SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQID NO:100, SEQ ID NO:101 or SEQ ID NO:102.

[0301] A93. A nucleic acid according to any one of embodiments A61-A65, wherein the first peptide comprises epidermal growth factor or a portion thereof.

[0302] A94. A nucleic acid according to embodiment A93, wherein the first peptide comprises the sequence SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, or SEQ ID NO:106.

[0303] A95. A nucleic acid according to any one of embodiments A61-A65, wherein the first peptide comprises a fibroblast growth factor or a portion thereof.

[0304] A96. A nucleic acid according to embodiment A96, wherein the first peptide comprises the sequence SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135 NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, or SEQ ID NO:144.

[0305] A97. A nucleic acid according to any one of embodiments A61-A65, wherein the first peptide comprises a DNA repair enzyme or a portion thereof.

[0306] A98. A nucleic acid according to embodiment A97, wherein the DNA repair enzyme or a portion thereof is derived from a base excision repair enzyme.

[0307] A99. A nucleic acid according to any one of embodiments A97 or A98, wherein the DNA repair enzyme comprises the amino acid sequence SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, or SEQID NO:155.

[0308] A100. A nucleic acid according to embodiment A97, wherein the DNA repair enzyme or a portion thereof is derived from an enzyme for directly reversing damage.

[0309] A101. The nucleic acid of embodiment A97 or A100, wherein the DNA repair enzyme comprises the amino acid sequence of SEQ ID NO:156, SEQ ID NO:157, or SEQ ID NO:158.

[0310] A102. A nucleic acid according to embodiment A97, wherein the DNA repair enzyme or a portion thereof is derived from a mismatch excision repair enzyme.

[0311] A103. The nucleic acid according to embodiment A97 or A103, wherein the DNA repair enzyme comprises the amino acid sequence SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, or SEQ ID NO:168.

[0312] A104. A nucleic acid according to embodiment A97, wherein the DNA repair enzyme or a portion thereof is derived from a nucleotide excision repair enzyme.

[0313] A105. The nucleic acid according to embodiment A97 or A104, wherein the DNA repair enzyme comprises the amino acid sequence SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO:172,SEQ ID NO:173,SEQ ID NO:174,SEQ ID NO:175,SEQ ID NO:176,SEQ ID NO:177,SEQ ID NO:178,SEQ ID NO:179,SEQ ID NO:180SEQ ID NO:181,SEQID NO:182,SEQ ID NO:183,SEQ ID OR NO:197.

[0314] A106. A nucleic acid according to embodiment A97, wherein the DNA repair enzyme or a portion thereof is derived from an editing or processing nuclease.

[0315] A107. A nucleic acid according to embodiments A97 or A106, wherein the DNA repair enzyme comprises the amino acid sequence SEQ NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, or SEQ ID NO:205.

[0316] A108. A nucleic acid according to any one of embodiments A61-A65, wherein the first peptide comprises telomerase or a portion thereof.

[0317] A109. A nucleic acid according to embodiment A108, wherein the telomerase comprises the amino acid sequence of SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, or SEQ ID NO:209.

[0318] A110. The nucleic acid of any one of embodiments A61-A65, wherein the first peptide comprises a protector of telomerase protein 1 or a portion thereof.

[0319] A111. The nucleic acid according to embodiment A110, wherein the protector of telomerase protein 1 comprises the amino acid sequence SEQ ID NO:210 or SEQ ID NO:211.

[0320] A112. A nucleic acid according to any one of embodiments A61-A65, A68-A76 or A79-A111, which further comprises a third nucleic acid sequence encoding a second peptide, and wherein the third nucleic acid sequence is located between the first nucleic acid sequence encoding the operon sequence and the second nucleic acid sequence encoding the first peptide.

[0321] A113. A nucleic acid according to any one of embodiments A61-A65, A68-A76 or A79-A111, which further comprises a third nucleic acid sequence encoding a second peptide, and wherein the third nucleic acid sequence is connected to the second nucleic acid sequence encoding the first peptide at the opposite end of the first nucleic acid sequence encoding the operon sequence.

[0322] A114. The nucleic acid of embodiment A112 or A113, wherein the second peptide comprises SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17 SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27 SEQ ID NO:28, SEQ ID NO:29,SEQ ID NO:30,SEQ ID NO:31,SEQ ID NO:32,SEQ ID NO:33,SEQID NO:34,SEQ ID NO:35,SEQ ID NO:36,SEQ ID NO:37SEQ ID NO:38,SEQ ID NO:39,SEQID NO:45,SEQ ID NO:46,SEQ ID NO:47SEQ ID NO:48,SEQ ID NO:49,SEQ ID NO:50,SEQID NO:51,SEQ ID NO:52,SEQ ID NO:53,SEQ ID NO:54,SEQ ID NO:55,SEQ ID NO:56,SEQID NO:57,SEQ ID NO:58,SEQ ID NO:59,SEQ ID NO:60,SEQ ID NO:61,SEQ ID NO:62,SEQID NO:63,SEQ ID NO:64,SEQ ID NO:65,SEQ ID NO:66,SEQ ID NO:67 SEQ ID NO:68,SEQID NO:69,SEQ ID NO:70,SEQ ID NO:71, SEQ ID NO:72,SEQ ID NO:73,SEQ ID NO:74,SEQ ID NO:75,SEQ ID NO:76,SEQID NO:77 SEQ ID NO:78,SEQ ID NO:79,SEQ ID NO:80,SEQ ID NO:81,SEQ ID NO:82,SEQID NO:83,SEQ ID NO:84,SEQ ID NO:85,SEQ ID NO:86,SEQ ID NO:87 SEQ ID NO:88,SEQID NO:89,SEQ ID NO:90, SEQ ID NO:91,SEQ ID NO:92,SEQ ID NO:93,SEQ ID NO:94,SEQ ID NO:95,SEQID NO:96,SEQ ID NO:97 SEQ ID NO:98,SEQ ID NO:99,SEQ ID NO:100,SEQ ID NO:101,SEQ ID NO:102,SEQ ID NO:103,SEQ ID NO:104,SEQ ID NO:105,SEQ ID NO:106,SEQ IDNO:107 SEQ ID NO:108,SEQ ID NO:109,SEQ ID NO:110,SEQ ID NO:111,SEQ ID NO:112,SEQ ID NO:113,SEQ ID NO:114,SEQ ID NO:115,SEQ ID NO:116,SEQ ID NO:117 SEQ IDNO:118,SEQ ID NO:119,SEQ ID NO:120,SEQ ID NO:121,SEQ ID NO:122,SEQ ID NO:123,SEQ ID NO:124,SEQ ID NO:125,SEQ ID NO:126,SEQ ID NO:127 SEQ ID NO:128,SEQ IDNO:129,SEQ ID NO:130,SEQ ID NO:131,SEQ ID NO:132,SEQ ID NO:133,SEQ ID NO:134,SEQ ID NO:135,SEQ ID NO:136,SEQ ID NO:137 SEQ ID NO:138,SEQ ID NO:139,SEQ IDNO:140,SEQ ID NO:141,SEQ ID NO:142,SEQ ID NO:143,SEQ ID NO:144,SEQ ID NO:145,SEQ ID NO:146,SEQ ID NO:147 SEQ ID NO:148,SEQ ID NO:149,SEQ ID NO:150,SEQ IDNO:151,SEQ ID NO:152,SEQ ID NO:153,SEQ ID NO:154,SEQ ID NO:155,SEQ ID NO:156,SEQ ID NO:157 SEQ ID NO:158,SEQ ID NO:159,SEQ ID NO:160,SEQ ID NO:161,SEQ IDNO:162,SEQ ID NO:163,SEQ ID NO:164,SEQ ID NO:165,SEQ ID NO:166,SEQ ID NO:167SEQ ID NO:168,SEQ ID NO:169,SEQ ID NO:170,SEQ ID NO:171,SEQ ID NO:172,SEQID NO:173,SEQ ID NO:174,SEQ ID NO:175,SEQ ID NO:176,SEQ ID NO:177 SEQ ID NO:178,SEQ ID NO:179,SEQ ID NO:180,SEQ ID NO:181,SEQ ID NO:182,SEQ ID NO:183,SEQID NO:184,SEQ ID NO:185,SEQ ID NO:106,SEQ ID NO:187SEQ ID NO:188,SEQ ID NO:189,SEQ ID NO:190,SEQ ID NO:191,SEQ ID NO:192,SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197 SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207 SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, or SEQ ID NO:211, and wherein the second peptide does not comprise the amino acid sequence of the first peptide.

[0323] A115. A nucleic acid according to any one of embodiments A61-A65, A68-A76 or A79-A111, which further comprises a nucleic acid sequence encoding a secretory peptide, and wherein the nucleic acid sequence encoding the secretory peptide is located between the operator sequence and the second nucleic acid sequence encoding the first peptide.

[0324] A116. A nucleic acid according to any one of embodiments A61-A65, A68-A76 or A79-A111, which further comprises a nucleic acid sequence encoding a secretory peptide, and wherein the nucleic acid sequence encoding the secretory peptide is linked at one end to the second nucleic acid sequence encoding the first peptide and at the opposite end of the operator sequence.

[0325] A117. A nucleic acid according to any one of embodiments A112-A114, which further comprises a nucleic acid sequence encoding a secretory peptide, and wherein the nucleic acid sequence encoding the secretory peptide is connected to the second nucleic acid sequence encoding the first peptide or the third nucleic acid sequence encoding the second peptide, and wherein the nucleic acid sequence encoding the secretory peptide is located between the nucleic acid encoding the operon and the second nucleic acid sequence encoding the first peptide or the third nucleic acid sequence encoding the second peptide.

[0326] A118. A nucleic acid according to any one of embodiments A112-A114, which further comprises a nucleic acid sequence encoding a secretory peptide, and wherein the nucleic acid sequence encoding the secretory peptide is connected to the second nucleic acid sequence encoding the first peptide or the third nucleic acid sequence encoding the second peptide, and wherein the nucleic acid sequence encoding the secretory peptide is located at opposite ends of the nucleic acid encoding the operon.

[0327] A119. A nucleic acid according to any one of embodiments A115-A118, wherein the signal sequence for secretion comprises the sequence SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, or SEQ ID NO:216.

[0328] A120. The nucleic acid of any one of embodiments A57-A119, wherein the nucleic acid is optimized for protein expression by computational methods.

[0329] A121. A cell comprising any of the nucleic acids of any embodiment or embodiments A57-A120.

[0330] A122. The cell of embodiment A121, wherein the cell comprises a genome having a mutation or a gene knockout.

[0331] A123. The cell of embodiment A121 or A122, wherein the cell is a bacterial cell.

[0332] A124. The cell of embodiment A121 or A122, wherein the cell is a fungal cell.

[0333] A125. The cell of any one of embodiments A121-A122, wherein the cell is from the genus Propionibacterium.

[0334] A126. The cell of any one of embodiments A121-A122 or A125, wherein the cell is Propionibacterium acnes.

[0335] A127. The cell of any one of embodiments A121-A122, wherein the cell is from the genus Corynebacterium.

[0336] A128. The cell of any one of embodiments A121-A122 or A127, wherein the cell is Corynebacterium striatum.

[0337] A129. The cell of any one of embodiments A121-A122, wherein the cell is from the genus Staphylococcus.

[0338] A130. The cell of any one of embodiments A121-A122 or A129, wherein the cell is Staphylococcus epidermidis.

[0339] A131. The cell of any one of embodiments A121-A122, wherein the cell is from the genus Streptococcus.

[0340] A132. The cell of any one of embodiments A121-A122 or A131, wherein the cell is Streptococcus thermophilus.

[0341] A133. The cell of any one of embodiments A121-A122, wherein the cell is from the genus Lactobacillus.

[0342] A134. The cell of any one of embodiments A121-A122 or A133, wherein the cell is Lactobacillus acidophilus.

[0343] A135. The cell of any one of embodiments A121-A122, wherein the cell is from the genus Lactococcus.

[0344] A136. The cell of any one of embodiments A121-A122 or A135, wherein the cell is Lactococcus lactis.

[0345] A137. The cell of any one of embodiments A121-A122, wherein the cell is from the genus Actinobacteria.

[0346] A138. The cell of any one of embodiments A121-A122, wherein the cell is from the genus Micrococcus.

[0347] A139. The cell of any one of embodiments A121-A122, wherein the cell is from the genus Demodex.

[0348] A140. The cell of any one of embodiments A121-A122, wherein the cell is from the genus Malassezia.

[0349] A141. The cell of any one of embodiments A121-A122, wherein the cell is from the genus Escherichia.

[0350] A142. The cell of any one of embodiments A121-A122 or A142, wherein the cell is Escherichia coli.

[0351] A143. The cell of any one of embodiments A121-A142, wherein the cell is non-pathogenic.

[0352] A144. The cell of embodiment A121, A122 or A124, wherein the cell is from the genus Candida.

[0353] A145. The cell of any one of embodiments A121, A122, A124 or A144, wherein the cell is Candida albicans.

[0354] A146. The cell of any one of embodiments A121, A122, A124 or A144, wherein the cell is Candida glabrata.

[0355] A147. The cell of any one of embodiments A121, A122, A124 or A144, wherein the cell is Candida tropicalis.

[0356] A148. The cell of any one of embodiments A121, A122, A124 or A144, wherein the cell is Candida parapsilosis.

[0357] A149. The cell of any one of embodiments A121, A122, A124 or A144, wherein the cell is Candida clausii.

[0358] A150. The cell of any one of embodiments A121-A149, wherein the mutation or knockout is in a lipase gene.

[0359] A151. The cell of any one of embodiments A121-A149, wherein the mutation or knockout is in a gene encoding for nutrient synthesis.

[0360] A152. The cell of any one of embodiments A121-A149, wherein the mutation or knockout is in a gene encoding a pathogenic biomolecule.

[0361] A153. The cell of any one of embodiments A121-A123, A125-A126 or A152, wherein the cell comprises a genome having a mutation or knockout in a gene encoding glutamine synthetase.

[0362] A154. The cell of any one of embodiments A121-A123, A125-A126 or A152, wherein the cell comprises a genome having a mutation or knockout in a gene encoding asparagine synthetase.

[0363] A155. The cell of any one of embodiments A121-A123, A125-A126 or A152, wherein the cell comprises a genome having a mutation or knockout in a gene encoding an aspartate kinase.

[0364] A156. The cell of any one of embodiments A121-A123, A125-A126 or A152, wherein the cell comprises a genome having a mutation or knockout in a gene encoding aspartate semialdehyde dehydrogenase.

[0365] A157. The cell of any one of embodiments A121-A123, A125-A126 or A152, wherein the cell comprises a genome having a mutation or knockout in a gene encoding for methionine synthesis.

[0366] A158. A topical formulation comprising the cell of any one of embodiments A121-A157 and a carrier for said cell.

[0367] A159. A method for treating, inhibiting or ameliorating a disorder in a subject by delivering a controlled expressed peptide, comprising administering to the subject the topical formulation of embodiment A158 for controlled delivery of the peptide.

[0368] A160. The method of embodiment A159, wherein the disease is acne, rosacea, alopecia, onychomycosis, underarm odor, graying hair, skin inflammation, skin discoloration, aging damage, chronic skin wounds, skin inflammation, nail fungus, autoimmune disease or hemophilia.

[0369] A161. The method of embodiment A159 or A160, wherein said administering comprises placing said composition on the epidermis.

[0370] A162. The method of any one of embodiments A159-A161, further comprising controlling expression of the peptide, wherein the controlling is performed by administering a second compound.

[0371] A163. A method according to embodiment A162, wherein the second compound is lactose.

[0372] A164. A method according to embodiment A162, wherein the second compound is tryptophan.

[0373] A165. The method of any one of embodiments A159-A164, further comprising controlling proliferation of the cells, wherein controlling proliferation is performed by administering a third compound.

[0374] A166. A method according to embodiment A165, wherein the third compound is a nutrient.

[0375] A167. A method according to embodiment A165 or A166, wherein the third compound is an amino acid.

[0376] A168. The method of any one of embodiments A165-A67, wherein the third compound is glutamine.

[0377] A169. A method according to any one of embodiments A165-A67, wherein the third compound is asparagine.

[0378] A170. A method according to any one of embodiments A165-A67, wherein the third compound is aspartic acid.

[0379] A171. A method according to any one of embodiments A165-A67, wherein the third compound is methionine.

[0380] B1. Use of a composition comprising a genetically modified bacterium of the genus Propionibacterium disclosed herein for treating a skin or nail disease in a mammal, wherein the bacterium comprises a nucleic acid encoding one or more mammalian growth factors and / or one or more mammalian cytokines.

[0381] B2. The use of the bacterium according to embodiment B1, wherein the mammal is a human, a dog or a cat.

[0382] B3. The use of the bacteria according to embodiment B1 or B2, wherein the skin or nail disorder comprises acne, actinic keratosis, alopecia areata, athlete's foot, onychomycosis, atopic dermatitis, axillary osmidrosis, eczema, fungal nail infection, psoriasis, rosacea, chronic wound healing, folliculitis, keratosis pilaris, perioral dermatitis, angiofibroma, skin inflammation, aging damage, skin discoloration, premature graying of hair or seborrhea.

Claims

1. A composition for topical or mucosal administration to a mammal, the composition comprising a genetically modified Propionibacterium acnes (P. acnes) type II, ribotype 6 strain, the strain comprising a nucleic acid encoding a mammalian growth factor or a mammalian cytokine, wherein the nucleic acid includes a regulatory element that drives expression of the mammalian growth factor or the mammalian cytokine in the P. acnes strain, the P. acnes strain comprising an endogenous CRISPR array, and the nucleic acid and regulatory element are integrated into the genome of the P. acnes strain.

2. The composition according to claim 1, wherein the mammalian growth factor is (a) Hormones; (b) human or bovine hormones; (c) growth hormone, wherein the growth hormone preferably comprises SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48 or SEQ ID NO:49; (d) secreted by Propionibacterium acnes strains; (e) human growth factor; (f) selected from transforming growth factor β (TGF-β), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), fibroblast growth factor (FGF), insulin-like growth factor-1 (IGF1), platelet-derived growth factor (PDGF), granulocyte monocyte colony stimulating factor (GMCSF) and epidermal growth factor (EGF); (g) transforming growth factor comprising any one of SEQ ID NO: 63 to SEQ ID NO: 69, or hepatocyte growth factor comprising SEQ ID NO: 70; (h) vascular endothelial growth factor (VEGF) comprising any one of SEQ ID NO: 71 to SEQ ID NO: 91; (i) platelet-derived growth factor (PDGF) comprising any one of SEQ ID NO: 93 to SEQ ID NO: 102; (j) epidermal growth factor (EGF) comprising any one of SEQ ID NO: 103 to SEQ ID NO: 106; or (k) a fibroblast growth factor (FGF) comprising any one of SEQ ID NO: 107 to SEQ ID NO:

144.

3. The composition according to claim 1, wherein (a) Propionibacterium acnes strains secrete mammalian cytokines; (b) mammalian cytokines are immunosuppressive cytokines; (c) the mammalian cytokine is a human cytokine; (d) a cytokine selected from the group consisting of interleukin-10 (IL-10), interleukin-6 (IL-6), interleukin-7 (IL-7) and interleukin-8 (IL-8), wherein preferably the cytokine is selected from the group consisting of SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27 and SEQ ID NO: 28; or (e) The mammalian cytokine comprises IL-10, wherein preferably the IL-10 comprises SEQ ID NO:

25.

4. The composition of claim 1, wherein the nucleic acid comprises an inducible promoter configured to regulate expression of a mammalian growth factor or a mammalian cytokine.

5. The composition of claim 1, wherein the nucleic acid (a) is under the control of an endogenous promoter that directs the expression of a mammalian growth factor or a mammalian cytokine; or (b) comprises an endogenous promoter configured to direct expression of a mammalian growth factor or a mammalian cytokine; wherein preferably, the inducible promoter or the endogenous promoter comprises a lacZ promoter or a lacZ operator, or an ara operator promoter.

6. The composition of claim 1, wherein the nucleic acid encoding a mammalian growth factor or a mammalian cytokine is inserted into all or part of an endogenous gene encoding a pathogenic protein.

7. The composition of claim 1, wherein the expression of endogenous protein is significantly reduced or eliminated.

8. The composition according to claim 1, wherein the expression of pathogenic proteins is significantly reduced or eliminated, wherein preferably the pathogenic proteins include endotoxins and / or exotoxins, or the endogenous pathogenic proteins include glyceraldehyde 3-phosphate dehydrogenase (GADPH) protein or CAMP protein.

9. The composition according to claim 1, comprising an inducible promoter for regulating the expression of an essential protein, wherein preferably (a) the essential protein is selected from the group consisting of chromosome replication initiation protein DnaA, FtsA, FtsI, FtsL, FtsK, FtsN, FtsQ, FtsW, FtsZ, ZipA, aroE, atpD, gmk, guaA, lepA, recA and sodA; (b) Inducible promoters can be induced by sugars, preferably lactose or arabinose; (c) an inducible promoter can be induced by an amino acid; or (d) Inducible promoters can be induced by synthetic amino acids.

10. The composition of claim 1, wherein the P. acnes strain has multiple genetic modifications, wherein the P. acnes strain has the following modifications: 1) the expression of endogenous proteins is significantly reduced or eliminated; and 2) an inducible promoter regulates the expression of essential proteins.

11. A composition comprising a plurality of genetically modified P. acnes strains of claim 1, wherein each P. acnes strain has a plurality of genetic modifications, and wherein the P. acnes strain has the following modifications: 1) expression of an endogenous protein is significantly reduced or eliminated; 2) an inducible promoter regulates expression of an essential protein.

12. A genetically modified Propionibacterium acnes (P. acnes) type II, ribosome type 6 strain comprising: a) mammalian growth factor or human IL-10, wherein the mammalian growth factor or IL-10, respectively, is secreted; and b) an inducible promoter that directs the expression of an essential protein selected from the group consisting of chromosome replication initiator proteins DnaA, FtsA, FtsI, FtsL, FtsK, FtsN, FtsQ, FtsW, FtsZ, ZipA, aroE, atpD, gmk, guaA, lepA, recA and sodA; in, The expression of endogenous CAMP2 and / or endogenous GADPH protein is significantly reduced or eliminated in the genetically modified P. acnes strain.

13. A composition comprising the genetically modified Propionibacterium acnes type II, ribotype 6 strain of claim 12, wherein preferably, the composition (a) is formulated for topical or mucosal administration to a mammal; or (b) comprises a sugar or an amino acid, wherein the inducible promoter is induced or stimulated by the presence of the sugar or the amino acid.

14. The genetically modified P. acnes strain or composition according to any one of claims 1 to 13, for use in a method of treating a skin or nail disease.

Citation Information

Cited By

  • Propionibacterium acnes VB208 gene editing method and application thereof

    CN120173837A